Validation of the iPad Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) by Corfield, Freya
 
 
1 
 
 
 
Validation of the iPad Brief International Cognitive Assessment for Multiple Sclerosis 
(BICAMS)  
 
Freya Corfield 
 
June, 2018 
 
 
 
 
 
 
 
 
 
 
 
 
 
Research submitted in partial fulfilment of the requirements for the degree of Doctor 
in Clinical Psychology (DClinPsy), Royal Holloway, University of London 
 
 
2 
 
Acknowledgements 
 
[Removed from online version] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
 
 
[Removed from online version] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 
 
Table of Contents 
 
1. Executive Summary ….……………..…………………………………………………………………11 
1.1 General background ……………………………………………………………………………..11 
1.2 Systematic review …….…………………………………………………………………………..13 
1.3 Empirical chapter …..……………………………………………………………………………..15 
1.4 Integration, Impact and Dissemination Summary ……………………….….…….19 
2. Systematic Review…………………………………………………………………………………..….20 
2.1. Abstract …………………………………………………………………..………………………..…20 
2.2. Introduction ………..……………………………………………………………………………….22 
2.2.1. Multiple Sclerosis………………………………………………………………………………22 
2.2.2. Clinical Features of Multiple Sclerosis ……..………………………………………..22 
2.2.3. Multiple Sclerosis Subtypes ………………………………………………………………23 
2.2.4. Cognition in Multiple Sclerosis ………………………………………………………….23 
2.2.5. Information Processing Speed in Multiple Sclerosis ………………………….24 
2.2.6. Immediate Verbal Recall in Multiple Sclerosis ………………….……………….25 
2.2.7. Immediate Visual Recall in Multiple Sclerosis ……………………………………25 
2.2.8. Other cognitive impairments in Multiple Sclerosis ……………………………26 
2.2.9. The impact of cognitive impairment in Multiple Sclerosis………………….26 
2.2.10. Cognitive assessment in Multiple Sclerosis….…………………………………..26 
2.2.11. Neuropsychological batteries in Multiple Sclerosis ….………………………27 
2.2.12. Brief International Cognitive Assessment for Multiple Sclerosis ………28 
2.2.13. Symbol Digit Modalities Test (SDMT) ………………………………………………29 
 
 
5 
 
2.2.14. California Verbal Learning Trials-II (CVLT-II).………………….………………..31 
2.2.15. Brief Visual Memory Test – Revised (BVMT-R) …………………….….………32 
2.2.16. Aim and research questions….…………………………………………………………33 
2.3. Method ……………………………………………………………………………………………….34 
2.3.1. Systematic Literature Search …………………………………………………………….35 
2.3.2. Eligibility Criteria ……..……………………………………………………………………….35 
2.3.3. Data extraction …………………………………………………………………………………38 
2.3.4. Quality assessment …………………………………………………………………………..39 
2.3.5. Statistical analysis ……………………………………………………………………………..39 
2.4. Results .…..……………………………………………………………………………………………41 
2.4.1. Systematic review of BICAMS validation studies ……………………………….41 
2.4.2. Quality rating ……………………………………………………………………………………46 
2.4.3. Sample recruitment …………………..……………………………………………………..48 
2.4.4. Sample size …..…………………………….…………………………………………………….48 
2.4.5. Gender ..……………………………………………………………………………………………49 
2.4.6. Average participant age in years …..…………………………………………………..50 
2.4.7. Diagnosis and selection criteria ………………………………………………………..50 
2.4.8. Type of MS .………………………………………………………………………………….……50 
2.4.9. Disease duration and time since diagnosis …………………………………..……51 
2.4.10. BICAMS type and mode of delivery …………………………………………………51 
2.4.11. Individual study summaries …………………………………………………………….51 
2.4.12. Meta-analysis of BICAMS validation studies ……………………………........65 
2.4.13. Symbol Digit Modalities Test (SDMT) .…………………………………………....65 
 
 
6 
 
2.4.14. California Verbal Learning Trials (CVLT-II) …………………………………….…68 
2.4.15. Brief Visual Memory Test Revised learning trials (BVMT-R)………..……68 
2.5. Discussion ……………………………………………………………………………………………72 
2.5.1. Summary of findings …………………………………………………………………………72 
2.5.2. Beyond the validation studies …………………………………………………………..73 
2.5.3. Impact on quality of life …………………………………………………………………….74 
2.5.4. Strengths …..……………………………………………………………………………………..75 
2.5.5. Limitations ………………………………………………………………………………………..76 
2.5.6. Recommendations ……..…………………………………………………………………….79 
2.5.7. Conclusions ………………………………………………………………………………………79 
3. Empirical study ..…………………………………………………………………………………………81 
3.1. Abstract …………………………….…………………………………………………………………81 
3.2. Introduction …...……………………………………………………………………………………83 
3.2.1. Multiple sclerosis …….………………………………………………………………………..83 
3.2.2. Phenotypes ….……………………………………………………………………………………84 
3.2.3. Cognitive impairment in Multiple Sclerosis …..…………………………………..84 
3.2.4. Information Processing Speed (IPS) in Multiple Sclerosis ………………….85 
3.2.5. Immediate Verbal Recall in Multiple Sclerosis ….……………………………….85 
3.2.6. Immediate Visual Recall in Multiple Sclerosis ……………..…………………….86 
3.2.7. Other cognitive impairments in Multiple Sclerosis ……………………………86 
3.2.8. The impact of cognitive impairment in Multiple Sclerosis …………………87 
3.2.9. Therapeutic interventions ..……………………………………………………………….87 
3.2.10. Assessing cognition in Multiple Sclerosis .………………………………………..88 
 
 
7 
 
3.2.11. Neuropsychological assessments ……………………………………………………88 
3.2.12. Brief International Cognitive Assessment for Multiple Sclerosis ……..89 
3.2.13. Computerised neuropsychological assessments …………………………….90 
3.2.14. Factors associated with cognitive ability ….……………………………………..91 
3.2.15. Mood and anxiety ………………….………………………………………………………92 
3.2.16. Fatigue ……………………………….………………………………………………………….92 
3.2.17 Dexterity ………………………………………………………………………………………..92 
3.2.18. Visual functioning ………….……………………………………………………………….93 
3.2.19. Premorbid functioning .………………………………………………………………….93 
3.2.20. Summary …………………………………………………………………………………..……93 
3.2.21. Aim …………………………………………………………………………………………………94 
3.2.22. Hypotheses ….…………………………………………………………………………………94 
3.3. Method ……………………………………………………………………………………………….95 
3.3.1. Research approval …………………………………………………………………………….95 
3.3.2. Sample and setting …………………………………………………………………………..96 
3.3.3. Material and measures ……………………………………………………………………..97 
3.3.4. Premorbid functioning ………………………………………………………………………97 
3.3.5. Cognition ………………………………………………………………………………………….97 
3.3.6. BICAMS …………………………………………………………………………………………….97 
3.3.7. iPad BICAMS ……………………………………………………………………………………100 
3.3.8. Associated factors …………………………………………………………………………..100 
3.3.9. Depression and anxiety …………………………………………………………………..100 
3.3.10. Fatigue ………………………………………………………………………………………….101 
 
 
8 
 
3.3.11. Visual Function ……………………………………………………………………………..102 
3.3.12. Dexterity ……………………………………………………………………………………….103 
3.3.13. Participant’s Feedback ………………………………………………………………….105 
3.3.14. Experimental design ……………………………………………………………………..105 
3.3.15. Procedure ……………………………………………………………………………………..106 
3.3.16. Power Analysis ………………………………………………………………………………106 
3.3.17. Statistical Analysis …………………………………………………………………………103 
3.4. Results ……………………………………………………………………………………………….109 
3.4.1. Descriptive and clinical characteristics of sample ……………………………109 
3.4.2. Associated factors ….……………………………………………………………………….110 
3.4.3. Premorbid functioning ……………………………………………………………………110 
3.4.4. Depression and anxiety ......................................................................111 
3.4.5. Fatigue ……..…………………………………………………………………………………….111 
3.4.6. Dexterity ……........................................................................................111 
3.4.7. Visual functioning ……………………………………………………………………………111 
3.4.8. Cognitive tests ....................................................................................112 
3.4.9. Correlations analysis ...........................................................................114 
3.4.10. Participant feedback ……………………………………………………………………..115 
3.5. Discussion ………………………………………………………………………………………….116 
3.5.1. Strengths ………………………………………………………………………………………..120 
3.5.2. Limitations ……………………………………………………………………………………...121 
3.5.3. Future directions …………………………………………………………………………….122 
3.5.4. Conclusion ………………………………………………………………………………………124 
 
 
9 
 
4. Integration, Impact and Dissemination …………………………………………………….125 
4.1. Introduction ……….……………………………………………………………………………..125 
4.2. Integration ….……………………………………………………………………………………..125 
4.3. Impact ……………………………………………………………………………………………….129 
4.4. Dissemination ……………………………………………………………………………………134 
4.4.1. Electronic dissemination ………………………………………………………………...134 
4.4.2. Non-electronic forms of dissemination …………………………………………..137 
4.5. Conclusion …………………………………………………………………………………………139 
5. References …………………………….…………………………………………………………………140 
6. Appendix ………………………………………………………………………………………………….179 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10 
 
Table of Tables and Figures 
 
Table 1: Study design and participant demographics of international validation 
studies…………………………………………………………………………………………………………………….43 
Table 2: Quality ratings of studies ………………………………..………………………………………..47 
Table 3: Comparison sample in BICAMS validation studies with actual number of 
individuals with Multiple Sclerosis (MS) in each country ………………………………………..49 
Table 4: Demographic and clinical characteristics of samples……………………………….107 
Table 5: Premorbid functioning, mood, fatigue, dexterity and visual functioning….109 
Table 6: BICAMS performance and level of agreement…………………………………………111 
 
Figure 1: PRISMA flowchart for selection process of studies in systematic review and 
meta-analysis………………………………………………………………………………………………………….37 
Figure 2: Forest plot for the Symbol Digit Modalities Test (SDMT)…………………………67 
Figure 3: Forest plot for California Verbal Learning Trials II (CVLT-II)………………………70 
Figure 4: Forest plot for the Brief Visual Memory Test Revised (BVMT-R)………………71 
 
 
 
 
 
 
11 
 
Validation of the iPad Brief International Cognitive Assessment for Multiple 
Sclerosis (BICAMS)  
 
1. Executive Summary 
This executive summary provides an overview of this thesis which was submitted as 
part of the fulfilment for the Doctorate in Clinical Psychology. The subsections 
include the current executive summary, a systematic review, an empirical study and 
the integration, impact and dissemination summary section.  
 
1.1. General background 
The leading cause of neurodisability amongst young adults is Multiple Sclerosis (MS), 
which is a chronic inflammatory and neurodegenerative disease of the central 
nervous system (CNS) (Thompson, Baranzini, Geurts, Hemmer, & Ciccarelli, 2018). 
Cognitive impairment is amongst a constellation of symptoms in MS. Presentations 
vary and symptoms include fatigue, pain, vision problems, mobility difficulties, sexual 
problems, bladder and bowel difficulties and speech and swallowing difficulties.  
Diagnosis is based on the most recent McDonald criteria, which has been 
recommended by the International Advisory Committee on Clinical Trials in Multiple 
Sclerosis (Thompson et al., 2017). Cognitive impairment remains absent from the 
diagnostic criteria for MS because of the difficulty of differential diagnosis with 
dementia. However cognitive impairment is experienced by half of individuals with 
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MS (Chiaravalloti & DeLuca, 2008) and it has major negative consequences for 
quality of life (Langdon, 2010). Therefore, cognitive assessment plays an important 
role in managing MS symptoms. Neuropsychological batteries are objective 
measures of cognition. Unlike patient self-report, neuropsychological batteries are 
not influenced by psychosocial factors like depression (Hanssen, Beiske, LandrØ, & 
Hessen, 2014). They are more sensitive in detecting cognitive impairment in 
individuals with MS than clinical interviews (Romero, Shammi, & Feinstein, 2015) or 
Magnetic Resonance Imaging (MRI) (Rocca et al., 2015). 
The most widely used neuropsychological battery was the Brief Repeatable Battery 
(BRB) (Rao & Group, 1990), followed by the more comprehensive Minimal 
Assessment of Cognitive Function in MS (MACFIMS) (Benedict et al., 2002). The 
batteries assessed a range of cognitive domains including Information Processing 
Speed (IPS), verbal and visual recall, attention, language and executive function 
through a variety of standardised tests. While these batteries offered several 
advantages to the validity of cognitive assessment over other techniques, issues 
emerged around the length of administration and the need for specialist training. 
The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) 
(Langdon et al., 2012) was developed almost a decade ago to overcome these 
challenges, by maintaining sensitivity of assessment whilst reducing test duration 
and need for specialist training. In essence the BICAMS was designed to operate as a 
brief assessment of cognition for small centres without specialist expertise. The 
BICAMS assesses the three most common cognitive impairments in MS, which 
includes IPS, immediate verbal and visual recall. The BICAMS can be completed in 
 
 
13 
 
under 15 minutes and requires only papers, pencil and a stopwatch. Most healthcare 
professionals could administer the BICAMS. 
 
1.2. Systematic Review 
Shortly following the development of the BICAMS was the publication of the 
international validation protocol (Benedict et al., 2012). Several countries embarked 
on validating the BICAMS within their populations. The aim of the systematic review 
was to summarise the findings of the studies produced as part this international 
collaboration.  
The keywords “multiple sclerosis” or “ms” were paired with “Brief International 
Cognitive Assessment for Multiple Sclerosis” or “BICAMS” in PubMed, PsycINFO, 
Medline and PsycArticles in January 2018. All titles and abstracts returned were 
examined against the following inclusion criteria: (a) peer-reviewed studies with no 
date restriction written in the English language; (b) samples including adults with any 
clinical subtype of MS (or subtype combination); and (c) studies which were 
undertaken as part of the international validation of the BICAMS protocol.  
If the studies met the above criteria, then they were considered for the meta-
analysis if they: (a) had a healthy control (HC) group; (b) reported standard 
quantitative information relevant to MS group and HC comparison group based on 
the subscales of the BICAMS: Symbol Digit Modalities Test (SDMT) for IPS (Smith, 
1982); the California Verbal Learning Test II (CVLT-II) for immediate verbal recall 
(Delis, Kramer, Kaplan & Ober, 2000); and the Brief Visual Memory Test - Revised 
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(BVMT-R) for immediate visual memory (Benedict, 1997); and (c) that there were a 
minimum of four studies which met this criteria, as specified by Rosenthal 
(Rosenthal, 1991).  
Sixteen studies met the criteria for the systematic review, of that total 14 were 
included in the meta-analysis. The authors extracted all of the relevant data. The 
quality of individual studies was rated by the authors (FC and DL) using the Effective 
Public Health Practice Project (EPHPP) (Thomas, Ciliska, Dobbins, & Micucci, 2004).  
The findings showed that the BICAMS had been validated in 14 individual countries, 
including America, Argentina, Belgium, Brazil, Canada, Czechoslovakia, Greece, 
Hungary, Iran, Ireland, Italy, Japan, Lithuania and Turkey. As part of this process, the 
BICAMS was translated into 11 individual languages, including Czech, Dutch, Greek, 
Hungarian, Italian, Japanese, Lithuanian, Persian, Portuguese, Spanish and Turkish. 
The pooled sample size was 1,649 MS cases and 1,528 HCs. To provide an indication 
of representation, the sample size per study was compared to the total number of 
those with MS in each country using the Atlas of MS (Browne et al., 2014).  
The contents of individual studies showed that gender ratio favoured females in 
every study but one. The gender ratio was only equal in two studies. The average age 
of participants was similar across studies. The mean age of people with MS was 
between 34 (sd= 10) to 45 years (sd= 9.93) and ranging between 34 (sd= 9.48) to 45 
years (sd= 9.9) for HC. Diagnosis of MS was based on the best current standards 
(Polman et al., 2011). Similar inclusion and exclusion recruitment criteria were 
reported between validation studies, although there was minor evidence of 
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discrepancy. Relapsing Remitting MS (RRMS) was the most common disease course 
studied, compared to progressive forms of the condition. The illness duration ranged 
from 6 years (sd= 5.08) to 13 years (sd= 7.16). Overall the quality of studies were 
rated between ‘Moderate’ to ‘Weak’ based on the EPHPP template (Thomas et al., 
2004). 
In terms of the question about internal validity of the BICAMS across heterogeneous 
populations, cognitive ability was consistently shown to be reduced in people with 
MS compared to HC. This was demonstrated by the results of a random-effects 
meta-analysis. IPS was the largest cognitive deficit (g= 0.943, 95% CI= 0.839, 1.046, p 
< .001). In addition immediate recall was found to be impaired, but to a lesser 
extent. Immediate verbal recall, with a medium effect size (g= 0.671, 95% CI= 0.539, 
0.804, p < .001) and recall of visual information with a medium effect size (g= 0.635, 
95% CI= 0.534, 0.736, p < .001).  
In conclusion, the review highlighted the extent to which the BICAMS had been 
validated internationally. Despite differences in study methodologies noted, the 
BICAMS was reliably shown to detect cognitive impairment in people with MS. This 
was most apparent in the domain of IPS. The BICAMS has been well evidenced as a 
standardised tool to assess the most common cognitive difficulties in MS.  
 
1.3. Empirical Chapter 
The iPad BICAMS was developed in 2018 to further improve cognitive assessment 
validity. The primary aim of this study was to establish the level of agreement 
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between the BICAMS iPad and the paper form. The level of agreement was expected 
to be high as all the physical parameters of the test were kept constant. Factors 
know to be associated with cognition in MS were expected to correlate with BICAMS 
scores. They included premorbid functioning, mood, fatigue, dexterity and visual 
functioning. The iPad BICAMS was thought to improve participant experience of 
cognitive assessments, thus it was hypothesised that participants would prefer iPad 
BICAMS.  
Ethical approval was provided by the North East - Tyne & Wear South Research 
Ethics Committee (ref: 17/NE/0352) and certified by Royal Holloway Research Ethics 
Committee. The inclusion criteria were: (a) diagnosis of MS based on McDonald 
criteria or equivalent (Polman et al., 2011); (b) aged between 18 - 65 years; (c) be 
born and educated in England; and (d) able to give informed consent. The exclusion 
criteria were: (a) another primary neurological or psychiatric condition that might 
separately contribute to cognitive impairment; and (b) a sensorimotor impairment 
that would confound the testing performance. 
The battery included nine elements. Premorbid functioning was assessed by the Test 
of Premorbid Functioning (TOPF) (Wechsler, 2011). Cognition was examined using 
two versions of the BICAMS (Langdon et al., 2012), the paper form and the newly 
developed iPad version. Self-reported depression and anxiety symptoms were 
assessed using the Hospital Anxiety and Depression Scale (HADS) (Zigmond & Snaith, 
1983). Perceived fatigue was measured by the Fatigue Severity Scale (FSS) (Krupp, 
LaRocca, Muir-Nash, & Steinberg, 1989). Dexterity was tested twice using the Nine-
Hole Peg Test (9HPT) (Mathiowetz, Weber, Kashman, & Volland, 1985) and the 
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Grooved Pegboard Test (GPT) which has higher motor planning demands (Matthews 
& Klove, 1964). High Contrast Visual Acuity (HCVA), Low Contrast Visual Acuity 
(LCVA; at 2.5% and 1.25%) and Letter Contrast Sensitivity (LCS), were measured using 
the Multiple Sclerosis Vision Test Battery (MSVTS) (Bullimore, 2016). Participants 
completed a short survey to examine their experiences of undertaking BICAMS.  
The study was a within-subjects cross-sectional counterbalanced randomised design. 
Using G*Power (Faul, Erdfelder, Lang, & Buchner, 2007) the specified sample size 
was 55 participants, holding an alpha at .05, with a power of .80. Data were 
investigated against the assumptions for parametric testing. 
Forty individuals with MS completed the battery. The majority of the sample were 
female (n=27, 67%), in full-time employment (n=19, 48%) and had a diagnosis of 
RRMS (n=32, 80%). The average age was 45 (sd= 11.70). Duration of illness varied 
and the mean was 11 years (sd= 9.90). The average duration of education was 16 
years (sd= 2.54). The sample had ‘fair’ mobility, according to the Hauser Ambulation 
Index ( =2, sd=2.70). 
The estimated level of premorbid functioning was in the ‘average’ range ( = 110, sd= 
12.25). Self-reported anxiety ( =8, sd= 4.11) and depression ( = 6, sd= 3.44) fell 
within the ‘normal’ to ‘mild’ range. Fatigue was above the threshold for suggested 
cut-off levels (m=42.75, sd=13.04). Dexterity was in the moderate range (9HPT, 
m=24 seconds, 7.3; GPT, m=111 seconds; sd=44). Visual functioning was better for 
HCVA (m=.10; sd=.17), which fell in the normal vision range, than it was for LCVA 
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(2.5%: m=.50, sd=.16; 1.25%: m=.73, sd=.10). LCS was below that signifying normal 
contrast sensitivity (m=1.89; sd=.21). 
Three randomised intra-class correlations (ICC) confirmed the first hypothesis, they 
showed that the level of agreement was a satisfactory level between paper and iPad 
BICAMS. The ICC was greatest for the SDMT subscale (ICC = .85, 95% CI (0.74, 0.92), p 
< .001), followed by the BVMT-R (ICC = .67, 95% CI (0.45, 0.62), p < .001) and CVLT-II 
(ICC = .57, 95% CI (0.32, 0.75), p < .001). BICAMS iPad took 13 minutes (sd= 2.61) on 
average to complete. An order effect was observed in the CVLT-II. Participants 
performed more poorly if they received the paper version first (F (1, 39) 19.754, p < 
.001). 
There was minimal support for the second hypothesis. Two significant correlations 
were found. The SDMT was significantly negatively associated with motor planning 
(r= -.469, p= .002). A linear regression revealed a significant relationship between 
SDMT and motor planning (p < .001). The R2 value was 0.22, thus 22% of the 
variation in SDMT could be explained by the model containing only motor planning. 
The BVMT-R was significantly negatively correlated with HCVA (r=-.459, p=.003). 
HCVA was within the normal range. 
Support for the third hypothesis was mixed. The majority of participants (70%) 
reported that they would be ‘moderately satisfied’ to ‘very satisfied’ to be tested by 
BICAMS iPad on an annual basis. However they simultaneously expressed 
indifference between the types of BICAMS used. Therefore they were not unhappy 
with the iPad BICAMS and were as happy to complete it as the paper version.  
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In summary, the BICAMS iPad scores show at least a satisfactory level of agreement 
with the paper version. Limited power may explain the lack of correlations found 
between associated factors. Most participants would be ‘moderately satisfied’ to 
‘very satisfied’ to be tested by BICAMS iPad annually. Therefore, with psychometric 
validation and participant endorsement, the BICAMS iPad could be used in routine 
clinical appointments in the future to monitor cognitive ability in MS. 
 
1.4. Integration, Impact and Dissemination Summary 
The subcomponents of the thesis will be disseminated in multiple formats to several 
audiences, including through scientific articles, conference posters and presentations 
and will be summarised by service-users on relevant MS specific websites. The 
chapters contained in this thesis are integrated well within the field of cognitive 
assessment in MS. Through international collaboration, the results of the systematic 
review show that the BICAMS has been standardised across heterogeneous samples 
and is a valid tool for assessing the most common types of cognitive impairment. The 
findings in the empirical study demonstrate the validity of the BICAMS iPad, which is 
arguably the next step in cognitive testing in MS. Overall these aspects highlight the 
feasibility, accessibility and effectiveness of brief cognitive assessment in MS, which 
have, up until now, been issues to address in the field.  
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2. Systematic Review 
 
A systematic review and meta-analysis of the Brief International Cognitive 
Assessment for Multiple Sclerosis (BICAMS) 
 
2.1. Abstract 
Multiple Sclerosis (MS) is a neurological disease of the central nervous system (CNS). 
A large proportion of those affected will experience cognitive impairment, which is 
linked with a worse prognosis. Therefore cognitive assessment is vital. 
Neuropsychological batteries for MS were available to measure cognitive 
impairment. Yet, there were issues related to need for specialist equipment and 
training and the length of batteries. The Brief International Cognitive Assessment for 
Multiple Sclerosis (BICAMS) was developed in 2010 as part of an international 
endeavour to optimise cognitive assessment. Several validation studies have been 
conducted as part of this project. The aim of this systematic review and meta-
analysis was to synthesise literature published as part of the international validation 
protocol. A literature search was performed in PubMed, PsychoInfo and Google 
Scholar in January 2018. Sixteen studies met the inclusion criteria. A pooled sample 
of 1,649 adults with MS and 1,528 healthy controls (HC) were included in the review. 
The BICAMS was found to be widely validated across 11 different languages and in 
14 individual cultures and locations. A meta-analysis was performed on 14 studies. 
The results showed that, compared to HC, adults with MS had significantly poorer 
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cognitive performance in all domains assessed by BICAMS, particularly in information 
processing speed. The most heterogeneous domain was immediate verbal recall, 
although this may have been related to language translation of the California Verbal 
Learning Trails II (CVLT-II). In conclusion the BICAMS has been shown to be a valid 
and reliable tool for assessing cognition in MS across heterogeneous samples at an 
international standard. Further validation studies are underway to support the 
protocol.  
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2.2. Introduction 
 
2.2.1. Multiple Sclerosis 
Multiple Sclerosis (MS) is the leading cause of neurodisability among young adults. 
There are approximately 127,000 people in the United Kingdom with the condition 
(Mackenzie, Morant, Bloomfield, MacDonald, & O’Riordan, 2014). MS is a chronic 
autoimmune, inflammatory neurological disease of the central nervous system (CNS) 
(Lublin, 2005). Inflammatory demyelination and, to a varying degree, axonal damage, 
underlies the condition (Thompson et al., 2018). Demyelination may lead to a 
reduction of conduction or complete failure of transmission. Axonal damage disrupts 
conduction, which produces symptoms when the slowing becomes critical (Katz, 
Sand & Lublin, 2013). 
 
2.2.2. Clinical Features of Multiple Sclerosis  
Neuropathic changes which result in damage to the CNS lead to a wide range of 
symptoms (Thompson et al., 2018), which include cognitive, motor, sensory, visual, 
bowel and bladder dysfunctions (Lassmann, 2010). Currently diagnosis of MS is 
based on the most recent McDonald criteria. The 2017 revisions were outlined by 
the International Advisory Committee on Clinical Trials in Multiple Sclerosis 
(Thompson et al., 2017). The guidelines stated that criteria for diagnosis of MS would 
require demonstration of dissemination of lesions in space (DIS) and time (DIT) and 
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the exclusion of alternative diagnoses based on a combination of clinical, imaging 
and laboratory tests. 
 
2.2.3. Multiple Sclerosis Subtypes 
There are four distinct MS disease courses (Achiron, Feldman, Magalashvili, Dolev, & 
Gurevich, 2012; Katz, Sand & Lublin, 2013; Thompson et al., 2018):  
(a) Relapsing Remitting MS (RRMS): This is the most common form of the condition. 
This course involves a discrete episode, which can include the optic nerve, brainstem 
or spinal cord, followed by remission;   
(b) Secondary-Progressive MS (SPMS): This is a progressive form of the disease, 
which accumulates disability. Approximately a third of individuals with RRMS will 
develop SPMS (15-30%), with or without superimposed relapses; 
(c) Primary Progressive MS (PPMS): This course is progressive form from the outset, 
15% of individuals with MS have PPMS;  
(d) Benign MS: This will occur in a minority of individuals with RRMS (15%), 
compared to the other phenotypes this disease course was not thought to develop 
significant neurological disability. 
 
2.2.4. Cognition in Multiple Sclerosis 
Cognitive impairment is highly prevalent in MS. Almost half of those with the 
condition will have a cognitive deficit (Chiaravalloti & DeLuca, 2008). Cognitive 
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impairment occurs across all phenotypes (Potagas et al., 2008), yet it is more 
common in progressive forms of the disease (Papathanasiou, Messinis, Georgiou, & 
Papathanasopoulos, 2014). A review showed that neuropsychological presentations 
among patients with MS are influenced by a wide range of factors, including 
genetics, sex, intelligence, disease course, comorbid neuropsychiatric illness and 
health behaviours (Benedict & Zivadinov, 2011). Cognition in MS impacts on 
employment, disease management, personality, and many aspects of psychosocial 
function (Bruce, Hancock, Arnett, & Lynch, 2010; Kavaliunas et al., 2017; Roy et al., 
2018).  
 
2.2.5. Information Processing Speed in Multiple Sclerosis  
Information Processing Speed (IPS) is the most prevalent cognitive impairment in MS 
(20 – 50%) (Grzegorski & Losy, 2017). This ability relates to the speed of processing a 
set amount of information (Kalmar & Chiaravalloti, 2007). The heterogeneity of 
previous study designs and tools to assess IPS have limited the ability to draw 
conclusions related to the nature of IPS dysfunction (Costa, Genova, DeLuca, & 
Chiaravalloti, 2016). It remains to be seen whether IPS represents the core cognitive 
deficit in MS (Denney, Lynch, Parmenter, & Horne, 2004), since it occurs 
concurrently with dysfunctions in other cognitive domains (Chiaravalloti & DeLuca, 
2008). 
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2.2.6. Immediate Verbal Recall in Multiple Sclerosis 
The second most typical cognitive impairment after IPS is verbal recall (33 – 65% 
prevalence) (Grzegorski & Losy, 2017). Many individuals with MS report difficulties 
with memory (Bobholz & Rao, 2003). Historically memory impairment was assessed 
though list-learning tests (e.g. (Rao, Hammeke, McQuillen, Khatri & Lloyd, 1984). 
Several previous meta-analysis have been conducted on verbal recall deficits in MS, 
however they are unable to provide a consensus regarding whether impairment 
relates to an acquisition or retrieval deficit (Lafosse, Mitchell, Corboy, & Filley, 2013 
Prakash, Snook, Lewis, Motl, & Kramer, 2008; Thornton & Raz, 1997; Wishart & 
Sharpe, 1997; Zakzanis, 2000). 
 
2.2.7. Immediate Visual Recall in Multiple Sclerosis 
People with MS experience difficulties with visual recall (20% to 26% prevalence) 
(Vleugels et al., 2000). This dysfunction refers to memory of visual information 
(Chiaravalloti & DeLuca, 2008). Relatively few studies have investigated visuospatial 
ability in individuals with MS, compared to other deficits such as in verbal recall 
(Grzegorski & Losy, 2017). Visuospatial difficulties are associated with reduced speed 
of processing (Costa et al., 2016). An impairment in visuospatial ability may have 
consequences for more higher-order functions (Bruce, Bruce, & Arnett, 2007).  
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2.2.8. Other cognitive impairments in Multiple Sclerosis 
There are a wide range of other cognitive functions which are impaired by MS. 
People with MS have difficulties in attention (12 – 25% prevalence) and executive 
functions (17-19% prevalence) (Grzegorski & Losy, 2017). People with MS show 
attention impairments across a range of tasks (Adler & Lembach, 2015; Beatty, Paul, 
Blanco, Hames, & Wılbanks, 1995; McCarthy, Beaumont, Thompson, & Peacock, 
2005). In addition they show difficulties in higher-order cognitive processes 
(Santiago, Guardia, Casado, Carmona, & Arbizu, 2007) and cognitive flexibility 
(Parmenter, Shucard, & Shucard, 2007).  
 
2.2.9. The impact of Cognitive Impairment in Multiple Sclerosis 
Cognitive impairment has a significant negative impact on quality of life, which is 
over and above physical impairments (Langdon, 2010). Cognitive impairment 
interferes with participatory activities including, employability (Morrow et al., 2010) 
and driving (Lincoln & Radford, 2008). Service-user safety can become compromised, 
as cognitive impairment increases risk for falls (Gunn, Newell, Haas, Marsden, & 
Freeman, 2013) and ability to adhere to drug treatment (Bruce et al., 2010).  
 
2.2.10. Cognitive assessment in Multiple Sclerosis 
Routine evaluation of cognition is useful to support early identification of cognitive 
impairment and plays a role in the management of disease progression (Benedict & 
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Zivadinov, 2011). Until recently cognitive assessments in MS were only performed in 
university hospitals or specialist MS centres. Importantly cognitive assessment can 
be challenging to achieve for a number of reasons. Service-users’ own self-report of 
cognitive ability is impacted upon by psychosocial variables, including depression 
(Hanssen et al., 2014). Clinical interviews, standard neurological examinations 
(Romero, Shammi, & Feinstein, 2015) and Magnetic Resonance Imaging (MRI) (Rocca 
et al., 2015) are not sensitive enough to detect cognitive impairment.  
 
2.2.11. Neuropsychological batteries in Multiple Sclerosis  
Neuropsychological tests are sensitive to cognitive impairment in MS. A few 
neuropsychological batteries have been developed to test objectively cognition in 
MS. In addition to these there are some brief assessment tools, which have been 
proposed to screen for cognitive impairment (e.g. Freitas , Batista, Afonso, Simões, 
de Sousa, 2016; Hansen et al., 2015; Hansen et al., 2017), although they differ in 
their validity and specificity of measurement and clinical thresholds. 
For the three decades, the most widely used neuropsychological battery was the 
Brief Repeatable Battery (BRB) (Rao & Group, 1990). This BRB includes the Selective 
Reminding Test (SRT) (Buschke & Fuld, 1974) (for verbal memory), the Symbol Digit 
Modality Task (SDMT) (Smith, 1982) (for information processing speed), the Paced 
Auditory Serial Addition Test (PASAT) (Gronwall, 1977) (for information processing 
speed), the 10/36 Spatial Memory Test (SPART 10/36) (Barbizet & Cany, 1968), and 
Word List Generation (WL) (for language skills) (Spreen & Benton, 1969). The 
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administration time for the BRB is 45 minutes. The BRB has been validated in several 
countries and has been frequently used in pharmacological trials.  
The Minimal Assessment of Cognitive Function in MS (MACFIMS) (Benedict et al., 
2002) was developed as a more comprehensive assessment of cognition in MS. In 
the MACFIMS, the 10/36 SPART (Barbizet & Cany, 1968) is replaced by the Brief 
Visuospatial Memory Test Revised (BVMT-R) (Benedict, 1997) for visual memory and 
the SRT (Buschke & Fuld) with the California Verbal Learning Test II (CVLT-II) (Delis, 
Kramer, Kaplan & Ober, 2000) for verbal memory. The tests which are added are the 
Judgement of Line Orientation (spatial skills) (Benton, Hamsher, Varney & Spreen, 
1983), the Delis–Kaplan Executive Function System (D-KEFS) (Baron, 2004) Sorting 
Task (executive skills – flexibility) and Controlled Oral Word Association Test (COWA, 
language) (Benton, Hamsher & Sivan, 1994). The administration time for the 
MACFMS is 90 minutes. Like the BRB, the MACFIMS has been validated in some 
other countries and has been used in research studies.  
While these batteries are precise enough to capture cognitive ability across a 
number of domains, they require a trained neuropsychologist for administration. 
This reduces their feasibility for widespread routine clinical assessment (e.g. Santos, 
Pinheiro & Barros, 2015). These batteries are limited for multinational trial use, as 
there are only a few countries with validations outside of the United States.  
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2.2.12. Brief International Cognitive Assessment for Multiple Sclerosis 
An expert consensus committee of seven neurologists and five neuropsychologists 
convened in June 2010 to develop recommendations for a screening assessment.  
The committee agreed to develop a brief monitoring tool, rather than cognitive 
screen or full assessment. Access and utility of the tool were among the primary 
concerns of the committee. To their knowledge, previous tests to evaluate cognition 
had not been internationally validated or standardised. The expert committee 
designed the Brief International Cognitive Assessment for Multiple Sclerosis 
(BICAMS) to optimise the assessment of cognition in MS across international centres 
where neuropsychologists are not available (Langdon et al., 2012). The BICAMS could 
be used by most healthcare professionals working with people with MS.  
The committee recommended that the BICAMS could be used for baseline and 
regular follow-up assessments which could be incorporated into routine clinical 
practice. The BICAMS was developed to be completed in less than 15 minutes. It 
does not require any special equipment (beyond paper, pens and a stopwatch). The 
committee critically evaluated the available cognitive scales and their psychometric 
properties. They decided that the BICAMS should assess the three most prevalent 
domains of cognition:  
 
2.2.13. Symbol Digit Modalities Test (SDMT) 
The Symbol Digit Modalities Test (SDMT) was selected to evaluate Information 
Processing Speed (IPS) (Smith, 1982). In the SDMT the participant is presented with a 
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record sheet which displays a nine-item key of single digits paired with abstract 
symbols. The digits are omitted from the remainder of the boxes. The participant is 
instructed to use the key to vocalise the corresponding numbers that should go in 
the empty boxes to match up with the symbols as fast as they can within a 90-
second limit. The total number of correct responses is calculated to generate an 
overall score (maximum score possible is 110). The SDMT can be completed within 5 
minutes, including the delivery of instructions, time allocated for practice and 
testing.  
The oral SDMT has good construct validity (Christodoulou et al., 2003), sensitivity 
(78-82%) and specificity (60-69%) to cognitive impairment in individuals with MS 
(Camp et al., 1999; Deloire et al., 2006; López-Góngora, Querol, & Escartín, 2015; 
Parmenter, Weinstock-Guttman, Garg, Munschauer, & Benedict, 2007; Strober et al., 
2009). As a tool the SDMT is highly sensitive to detect cognitive change (Amato et al., 
2010; Holmén et al., 2011; Morrow et al., 2010).  
The SDMT has the ability to distinguish adults with MS from Healthy Controls (HC) 
(Hughes, Denney, & Lynch, 2011; Langdon et al., 2012; O’Connell, Langdon, Tubridy, 
Hutchinson & McGuigan, 2015; Weinstock-Guttman, Morrow, Hojnacki Munschauer 
& Benedict, 2010). The SDMT has been broadly applied and the tool has been 
validated in several countries (Camp et al., 1999; Deloire et al., 2006; Strober et al., 
2009). The SDMT shows good external utility, since it correlates with current 
(Einarsson et al., 2006) and future employment status (Morrow et al., 2010). 
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2.2.14. California Verbal Learning Test-II (CVLT-II) 
The California Verbal Learning Test II (CVLT-II), five learning trials (Delis, Kramer, 
Kaplan & Ober, 2000) evaluates immediate verbal recall. The CVLT-II consists of a 16-
item pseudo-randomised list of English words approximating a shopping list. 
Participants are instructed to recall as many words as possible, in any order, across a 
series of five trials. In the task the examiner reads each word out loud at a rate of 
one word per second. Participants are asked to respond with as many words as they 
can recall in every trial, including the words that they have already reported in 
previous trials. The words contained in the task were selected for their frequency of 
use across multiple demographic variables. The words belong to four semantically 
categorised groups: animals, transport, vegetables and office furniture. A total score 
is generated from the sum of the correct number of words reported across the five 
trials (maximum score possible: 80). Total time to administer the CVLT-II trials 1-5 is 
5-10 minutes including instructions, testing and responses.  
The CVLT-II shows good sensitivity (61%) (Niccolai et al., 2015) and specificity to 
cognitive impairment in MS (Strober et al., 2009). The CVLT-II has high test-retest 
reliability (Delis, Kramer, Kaplan & Ober, 2000; Benedict, 2005). The full scale version 
of the CVLT-II has been shown to be able to differentiate employed MS patients from 
patients not employed due to MS (Stegen et al., 2010). 
The first five recall trials of the CVLT-II show a high degree of interdependence 
compared to other sections (Fink et al., 2010; Stegen et al., 2010) and thus the 
committee decided that they had sufficient psychometric rigour to be particularly 
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sensitive to MS impairment (Fink et al., 2010; Stegen et al., 2010). The psychometric 
properties outlined above should be considered as inferential as they do not utilise 
the other trials (including delayed recall, recognition, and category cued trials) 
(Langdon et al., 2012).  
 
2.2.15. Brief Visual Memory Test – Revised learning trials (BVMT-R) 
The Brief Visual Memory Test Revised (BVMT-R) learning trials (Benedict, 1997) 
assesses immediate visual recall. The BVMT-R comprises of 2 x 3 black geometric 
figures on a white background. Participants are instructed to observe the figures for 
the full display time of 10 seconds. The examiner removes the stimulus display from 
view. The participant is instructed to draw these shapes from memory in the correct 
position they were located on the stimulus sheet. This is repeated for three trials. 
Scoring is based on the accuracy of shapes and their location. The maximum scores 
possible is 12 for each trial, with an overall total of 36 possible for the whole task. 
The BVMT-R takes under 5 minutes to complete, including the instructions, display of 
the geometric figures and drawing time. 
The BVMT-R is highly sensitive to detect cognitive impairment in MS (60) (Benedict, 
Priore, Miller, Munschauer & Jacobs, 2001; Langdon et al., 2012; Niccolai et al., 
2015). The BVMT-R has good concurrent validity, as it correlates strongly with 
measures of explicit memory (r= .65 to .80) (Benedict, Schretlen, Groninger, Dobraski 
& Shpritz, 1996). Of note is that the psychometric properties of the assessment 
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should be considered inferentially, as the full scale version was not administered 
(Langdon et al., 2012). 
 
2.2.16. Aim 
In summary, cognitive impairment in MS has a significant negative impact on quality 
of life. Thus cognitive assessment is vital. The BICAMS was developed as a brief 
monitoring tool to assess the three most prevalent forms of cognitive impairment in 
MS, which include IPS and immediate and verbal and visual memory. The BICAMS 
overcomes several caveats of alternative forms of cognitive assessment in MS, 
including difficulties with patient report, and lack of sensitivity with clinical interview 
and MRI metrics. Neuropsychological batteries were developed to assess cognition 
in MS, although there are issues around access, including requirements of specialist 
training, specialist equipment and the test battery is lengthy.  
The BICAMS committee published an international validation protocol (Benedict et 
al., 2012) which outlines five criteria by which the BICAMS can be validated in other 
languages to facilitate comparison across settings. In the second conference the 
committee agreed that most normative data had been based on US samples, which 
increased interpretative error when referenced to raw scores derived from a 
different culture, language or country. Therefore the committee outlined validation 
criteria which was to (a) standardise test stimuli for the culture or language; (b) 
standardise and translate examiner instructions; (c) recruit a minimum sample of 65 
healthy controls matched to patients demographic; (d) establish test-retest reliability 
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over 1-3 weeks; and (e) establish criterion validity by comparing patient with control 
scores. The aim of the current systematic review and meta-analysis was to be the 
first to synthesise the BICAMS validation literature to investigate its accessibility. The 
meta-analysis is necessary for two reasons. Firstly, to calculate the effect size in 
cognitive impairment between MS cases and controls. Secondly, to understand the 
consistency of these effect sizes across different populations. 
 
Research questions 
Systematic Review 
How many countries have participated in the international validation of the 
BICAMS and what do their data show following translations of the BICAMS? 
Meta-analysis 
What are the effect sizes of the BICAMS subscales of cognitive impairment 
between MS cases and controls?   
 
2.3. Method 
A search in the Cochrane Database in January 2018 confirmed that no previous 
reviews had been published in the proposed area. Thus the current review is the first 
attempt to synthesise studies published as part of the international validation of the 
BICAMS. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
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(PRISMA) Statement (Moher et al., 2009) were followed for standardised 
undertaking and reporting of reviews.  
 
2.3.1. Systematic Literature Search 
The search terms “multiple sclerosis” or “ms” were paired with “Brief International 
Cognitive Assessment for Multiple Sclerosis” or “BICAMS” to identify studies which 
were conducted as part of the international validation protocol of the BICAMS. 
These keywords were searched for within the Title or Abstract of the databases 
PubMed, PsycINFO, Medline and PsycArticles in January 2018.  
 
2.3.2. Eligibility Criteria 
The following inclusion criteria for the current review were to be: (a) peer-reviewed 
studies with no date restriction written in the English language; (b) samples including 
adults with any clinical subtype of MS (or subtype combination); and (c) studies 
which were undertaken as part of the international validation of the BICAMS 
protocol. Studies which included the BICAMS, but were not part of the international 
validation of the BICAMS protocol, were excluded. This criterion was necessary to 
allow for investigation of a set of studies which were methodologically matched 
according to the guidelines set out in the international validation protocol (e.g. test 
order administration, instructions). 
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If studies met the above criteria for review, they were considered for meta-analysis 
inclusion if they included: (d) a healthy control (HC) comparison group; (e) reported 
standard quantitative information based on the subscales of SDMT, CVLT-II and 
BVMT-R (mean, standard deviation and sample size) of the MS cases and HC 
comparison group; and (f) that there were a minimum of four studies, as specified by 
Rosenthal (Rosenthal, 1991), which met the criteria to be included in a meta-
analysis. 
All titles and abstracts which were returned in the search were screened to examine 
the eligibility criteria. The full-texts of articles that met the eligibility criteria were 
accessed as part of the screening process (see Figure 1).  
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Figure 1. PRISMA flowchart for selection process of studies in systematic review and 
meta-analysis 
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2.3.3. Data extraction 
A headed table was used to guide the extraction of relevant information from 
articles in a consistent manner to assess their eligibility for inclusion in the review. 
The studies were extracted and organised by the authors (FC and DL) according to 
whether they met criteria for the systematic review and/or the meta-analysis. Three 
studies were identified through expert opinion (DL), one study was in press at the 
time of search (Niino et al., 2018) and in the two remaining articles the BICAMS was 
completed as part of a comprehensive test battery (Eshaghi et al., 2012; Strober et 
al., 2009). A total of 21 studies were excluded from the final review following data 
extraction. Sixteen studies were shortlisted. Several socio-demographic and clinical 
characteristics were extracted from these studies. These comprised of recruitment 
selection, diagnostic criteria, participant age, MS phenotype, MS disease duration 
and time since diagnosis of MS, years of education, score on the Expanded Disability 
Status Scale (Kurtzke, 1983) and characteristics of the control group.   
Of the above shortlisted studies, 14 studies included met the criteria for the meta-
analyses. The standard quantitative information based on the subscales of SDMT, 
CVLT-II and BVMT-R (mean, standard deviation and sample size) of the MS cases and 
HC comparison group were extracted from these studies for the meta-analysis. All of 
the relevant data included in the current review and meta-analysis were obtained 
from information presented in text, tables and graphs.  
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2.3.4. Quality assessment 
The Effective Public Health Practice Project (EPHPP) (Thomas et al., 2004) is an 
instrument which shows good test re-test reliability to examine the quality of studies 
in health care settings (Armijo-Olivo, Stiles, Hagen, Biondo, & Cummings, 2012). The 
EPHPP was used to rate the quality of studies included in the review. The EPHPP 
broadly examines quality of studies based on: selection bias, study design, 
confounders, blinding, data collection methods, and withdrawals or drop-outs. A 
total study quality score is based on the sum of the ratings for each of these 
dimensions. The two authors (FC and DL) independently rated studies according to 
the EPHPP and any disagreements were discussed and resolved.  
 
2.3.5. Statistical analysis 
The statistical software program Comprehensive Meta-Analysis version 3 
(Borenstein, Hedges, Higgins & Rothstein, 2005) was used to perform three meta-
analysis based on the averages of the subscales of SDMT, CVLT-II and BVMT-R. These 
subscales measure information processing speed, immediate verbal recall and visual 
recall respectively. Effect sizes were calculated as standardized mean differences 
with Hedges’ g and were interpreted within the following parameters: 0.2 = small; 
0.5 = medium; 0.8 = large. Hedges’ g was selected for this analysis as it corrects for 
any potential biases that occur from small sample sizes and because it offers the 
same interpretation as Cohen d (While Cohen’s d tends to overestimate the absolute 
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value of the standardized mean difference in small samples) (Hedges, Pustejoysky & 
Shadish, 2012). 
The random-effects model was selected to examine how much the MS group 
differed from the HC based on their performance across the former BICAMS 
subscales. The random effects model was selected over the fixed effects model as it 
assumes the observed estimates of treatment effect vary across studies due to 
actual differences in the treatment effect in each study as well as sampling variability 
(Riley, Higgins & Deeks, 2011). In the present study there could be variation within 
MS samples as a result of heterogeneous presentations (Disanto et al., 2011).  
The predicted direction was that adults with MS would have inferior cognitive 
performance across all subscales in contrast to HC. The random-effects model 
estimates a mean of a distribution of effects. Compared to the fixed-effect model, 
the random-effects model assumes that the allocation of study weights is based on 
the inverse of the total variance, which includes both within and between study 
variance. The fixed-effect model yields a wider confidence interval (CI) when there is 
significant heterogeneity among effect sizes.  
Two statistics were performed to examine heterogeneity, Cochrane’s Q was applied 
to examine for the presence of heterogeneity and the I2 statistic to investigate for 
the magnitude of heterogeneity. A significant Cochrane’s Q statistic indicates that 
variance occurring in the results may be due to dissimilar effect sizes across the 
studies included and sample or methodological differences. The proportion of the I2 
statistic can be interpreted as a small (25%), moderate (50%) or high (75%) level of 
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heterogeneity across studies and not due to random error (Higgins, Thompson, 
Deeks & Altman, 2003). 
Forest plots were created to display the effect sizes for each study. In addition they 
were visually inspected for the presence of any outliers. Further sensitivity analyses 
were performed to assess for publication bias. Funnel plots of standardized mean 
differences against standard error were produced and tested against Egger’s test of  
funnel plot asymmetry (Egger, Smith, Schneider & Minder, 1997) and Rosenthal’s 
fail-safe N (Rosenthal, 1991). If publication bias was indicated by a significant Egger 
test (Egger regression test: p < 0.1), then the trim and fill method (Duval & Tweedie, 
2000) for random-effects models was used to impute ‘missing studies’. This method 
compensates for funnel plot asymmetry with the adjusted pooled effect sizes and 
95% CIs reported after the addition of potential missing studies.  
 
2.4. Results 
2.4.1. Systematic review of BICAMS validation studies  
Presented in Table 1 are the details of the sixteen studies which met the criteria to 
be included in the systematic review. The international validation protocol for 
BICAMS has been widely applied across 14 different countries, including America, 
Argentina, Belgium, Brazil, Canada, Czechoslovakia, Greece, Hungary, Iran, Ireland, 
Italy, Japan, and Lithuania and Turkey. The BICAMS was validated twice in both Italy 
and Argentina. Through the international validation process the BICAMS has been 
translated extensively from its original form in English into 11 individual languages: 
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Czech, Dutch, Greek, Hungarian, Italian, Japanese, Lithuanian, Persian, Portuguese, 
Spanish and Turkish. The systematic review is organised by providing an overview of 
the results of the systematic review and then a detailed summary of each study for 
reference.   
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Reference  
(first author, date) 
 N Age  
m (sd) 
Sex  
(% f) 
Education  
m (sd) 
Phenotype 
(% RRMS) 
Duration 
m (sd) 
EDDS  
m (sd) 
SDMT 
m (sd) 
CVLT-II 
m (sd) 
BVMT-R 
m (sd) 
Costers  
(2017)  
MS 97 45  
(10) 
70 14  
(2) 
84 13  
(7) 
4 
(3) 
61  
(10) 
61  
(60) 
28  
(5) 
 HC 97 44  
(13) 
77 15  
(2) 
- - - 52  
(13) 
60  
(13) 
25  
(29) 
Dusankova  
(2012)  
MS 369 34  
(10) 
68 14  
(3) 
68 8  
(7) 
3  
(2) 
50  
(13) 
60  
(8) 
23  
(7) 
 HC 134 34  
(9) 
71 14  
(3) 
- - - 65  
(9) 
52  
(11) 
29  
(4) 
Eshaghi  
(2012)  
MS 156 34 
(9) 
71 14  
(3) 
80 6  
(5) 
3†  
(8)  
44  
(17) 
49  
(10) 
21  
(8) 
 HC 90 34  
(9) 
63 14  
(4) 
- - - 56  
(16) 
55  
(8) 
25  
(7) 
Giedraitienė 
(2015) 
MS 50 39  
(10) 
32 16  
(3) 
88 12 
(10) 
3  
(1) 
43  
(14) 
56  
(10) 
23  
(7) 
 HC 20 37 
(16) 
10 18  
(4) 
- - - 58  
(12) 
66  
(6) 
30  
(4) 
Goretti    MS - - - - - - - - - - 
(2014) HC 23  
243 
39  
(13)  
38  
(13) 
66  
65 
15  
(3) 
- - - 56  
(11) 
56  
(9) 
28  
(6) 
 
 
 
           
Table 1. Study design and participant demographics of international validation studies. 
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Reference  
(first author, date) 
 N Age  
m (sd) 
Sex  
(% f) 
Education  
m (sd) 
Phenotype 
(% RRMS) 
Duration 
m (sd) 
EDDS  
m (sd) 
SDMT 
m (sd) 
CVLT-II 
m (sd) 
BVMT-R 
m (sd) 
Niccolai  
(2015)  
MS 192 41  
(11) 
74 12  
(4) 
100 13  
(2) 
3  
(2) 
46  
(13) 
50 
(12) 
24 
 (8) 
HC 200 - - - - - - 56  
(11) 
56  
(9) 
28  
(6) 
Niino  
(2018)  
MS 156 41  
(10) 
69 14  
(2) 
88   2  
(2) 
48  
(14) 
49  
(13) 
24  
(8) 
 HC 126 39  
(12) 
72 14  
(2) 
- - - 61  
(10) 
56  
(11) 
28  
(5) 
O’Connell  
(2015)  
MS 67 44  
(12) 
73 14  
(3) 
70 10  
(9) 
2  
(1) 
46  
(13) 
45  
(10) 
18  
(7) 
 HC 66 43  
(13) 
68 14  
(3) 
- - - 56  
(11) 
54  
(9) 
21  
(7) 
Ozakbas  
(2017) 
MS 173 38  
(11) 
71 14  
(7) 
87 
 
9  
(6) 
2  
(2) 
43  
(13) 
46  
(11) 
17  
(9) 
HC 153 37  
(9) 
71 15  
(9) 
- - - 54  
(10) 
54  
(8) 
23  
(9) 
Polychroniadou 
(2016)  
MS 44 40 
(10) 
61 14  
(5) 
77 10  
(4) 
- 45  
(17) 
56  
(12) 
19  
(8) 
 HC 79 36  
(11) 
61 15  
(6) 
- - - 61  
(13) 
61  
(11) 
22  
(7) 
Sandi  
(2015)  
MS 65 42  
(9) 
75 n=34 > 13 
yrs 
100 11  
(8) 
3  
(2) 
56  
(16) 
55  
(11) 
23  
(9) 
 HC 65 41  
(12) 
75 n=34 > 13 
yrs 
- - - 67  
(12) 
59  
(8) 
27  
(6) 
 
 
           
Table 1. Continued.  
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Note. Brief Visuospatial Memory Test Revised (BVMT-R); California Verbal Learning Trials II (CVLT-II); Expanded Disability Status Scale 
(EDSS); f (female); Healthy Control (HC); m (mean); Multiple Sclerosis (MS); RRMS (relapse remitting multiple sclerosis); sd (standard 
deviation); Symbol Digit Modalities Test (SDMT); yrs (years); †=median value. 
Reference  
(first author, date) 
 N Age  
m (sd) 
Sex  
(% f) 
Education  
m (sd) 
Phenotype 
(% RRMS) 
Duration 
m (sd) 
EDDS  
m (sd) 
SDMT 
m (sd) 
CVLT-II 
m (sd) 
BVMT-R 
m (sd) 
Spedo  
(2015)  
MS 58 41  
(12) 
69 13  
(6) 
100 8  
(7) 
2  
(2) 
36  
(16) 
42  
(12) 
20  
(9) 
 HC 58 40  
(12) 
55 13  
(4) 
- - - 47  
(13) 
53  
(11) 
24  
(8) 
Strober  
(2009) 
MS 65 45  
(10) 
80 14  
(2) 
72 10  
(8) 
3  
(2)  
48  
(10) 
48  
(10) 
26  
(6) 
 HC 46 45  
(10) 
85 15  
(2) 
- - - 62  
(11) 
57  
(8) 
21  
(6) 
Vanotti  
(2017) 
MS 50 43  
(10) 
74 15  
(3) 
78 13  
(9) 
3  
(3) 
45  
(16) 
51  
(12) 
21  
(8) 
 HC - - - - - - - - - - 
Vanotti  
(2016)  
MS 50 43  
(10) 
74 15  
(3) 
78 13  
(9) 
3  
(3) 
45  
(16) 
51  
(12) 
21  
(8) 
 HC 100 42  
(10) 
75 15  
(2) 
- - - 57  
(11) 
61  
(10) 
23  
(6) 
Walker  
(2016)  
MS 57 45  
(10) 
72 15  
(3) 
77 10  
(8) 
3  
(2) 
50  
(11) 
52  
(10) 
27  
(7) 
 HC 51 42  
(11) 
86 16  
(2) 
- - - 59  
(8) 
58  
(8) 
30  
(4) 
Table 1. Continued.  
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2.4.2. Quality rating 
According to the EPHPP template (Thomas et al., 2004) the overall quality rating of 
studies included in the review ranged from ‘Moderate’ to ‘Weak’. Presented in Table 
2 are the quality ratings for the studies included in the systematic review. The EPHPP 
examines ratings in quantitative studies according to: selection bias, study design, 
confounders, blinding, data collection methods, and withdrawals or drop-out. A total 
quality rating can be derived from the individual ratings of the measures, which is 
shown in the final column.  
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Table 2. Quality assessment of studies validating the BICAMS  
Study  
(first author, 
year)  
Selection 
bias 
Study 
design 
Confounders Blinding Data 
collection 
method 
Withdrawals 
and drop 
out 
Overall 
quality 
rating 
Costers (2017) Strong Moderate Strong Weak Strong Strong Moderate 
Dusankova  
(2012) 
Strong Moderate Strong Weak Weak Strong Weak 
Eshaghi  (2012) Strong Moderate Strong Weak Weak Strong Weak 
Giedraitienė 
(2015) 
Strong Moderate Weak Weak Weak Strong Weak 
Niccolai  (2015) Moderate Moderate Weak Weak Weak Strong Weak 
Niino  (2018)        
O’Connell  
(2015) 
Strong Moderate Strong Weak Strong Strong Moderate 
Ozakbas  
(2017) 
Strong Moderate Strong Weak Strong Strong Moderate 
Polychroniadou 
(2017) 
Strong Moderate Weak Weak Weak Strong Weak 
Sandi (2015) Strong Moderate Weak Weak Weak Strong Weak 
Spedo  (2015) Moderate Moderate Strong Weak Weak Strong Weak 
Strober  (2009) Strong Moderate Strong Weak Strong Strong Moderate 
Vanotti, 
(2017a) 
Strong Weak Strong Weak Weak Strong Weak 
Vanotti 
(2017b) 
Strong Moderate Strong Weak Weak Strong Weak 
Walker  (2016) Strong Moderate Strong Weak  Strong Strong Moderate 
Overall quality rating: Strong = no weak ratings; Moderate = one weak rating; Weak 
= two or more weak ratings. 
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2.4.3. Sample recruitment 
MS participants were recruited to take part in the international validation protocol 
from a variety of sources, including university hospitals, MS centres, specialist clinics 
and tertiary referral centres, while HC were sampled from the community, were part 
of a normative sample or were known to the MS cases. 
 
2.4.4. Sample size  
The pooled sample size across the studies included was large. There were 1,649 
adults with MS compared to 1,528 healthy controls. The Atlas of MS is the most 
extensive global study of the epidemiology of MS (Browne et al., 2014). Presented in 
Table 3 is the sample size per study which was compared to that of the number of 
individuals documented using the Atlas per country with MS. Almost all studies 
included a case and control comparison, thirteen studies included a group of adults 
with MS and HC, while two studies did not. The studies which deviated from this 
design included only a single group of MS cases or HC. The sample size varied 
between studies, this ranged from 369 MS cases to 44 and from 200 HC to 20. Only 
three studies contained equal sample sizes between cases and controls. 
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Table 3. Comparison sample in BICAMS validation studies with actual number of 
individuals with Multiple Sclerosis (MS) in each country. 
Reference  
(first author, year) 
Country n per 
study 
n per  
country  
Percent 
represented 
Costers (2017) Belgium 97 12,000 0.81% 
Dusankova (2012) Czech Republic 369 16,000 2.31% 
Eshaghi (2012) Iran 156 50,000 0.31% 
Giedraitienė (2015) Lithuania 50 2,621 1.91% 
Niccolai (2015) Italy 192 68,000 0.03% 
Niino (in press) Japan 156 12,000 1.30% 
O’Connell (2015) Ireland 67 7,000 0.96% 
Ozakbas (2017) Turkey 173 40,000 0.43% 
Polychroniadou (2016) Greece 44 7,000 0.63% 
Sandi (2015) Hungary 65 20,000 0.33% 
Spedo (2015) Brazil 58 30,000 0.19% 
Strober (2009) United States 65 400,000 0.02% 
Vanotti (2016; 2017) Argentina 50 8,000 0.06% 
Walker (2016) Canada 57 97,366 0.06% 
     
 
2.4.5. Gender  
In the majority of studies the gender ratio was disproportionate, in the direction of 
females. MS is more common in females (e.g. Westerlind et al., 2014). In MS cases 
this ranged between 61% to 80% and 55% to 86% in the HC. A single study deviated 
from this representation, in this case there was a lower percentage of females in the 
sample than males (32% females with MS; 10% healthy females). The gender ratio 
was only equal in two studies (61% females and 75% HC).  
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2.4.6. Average participant age in years 
The age of participants included in the review was relatively consistent with similar 
standard deviations. The mean ages of adults with MS reported across the studies 
ranged from 34 (sd= 10) to 45 (sd= 9.93) and for HC from 34 (sd= 9.48) to 45 
(sd=9.9). The pooled age across studies was comparable, 39 years for adults with MS 
and 40 years for HC. 
 
2.4.7. Diagnosis and selection criteria  
The most common reported form of diagnosis of MS was through the revised 
McDonald criteria (Polman et al., 2011) or later versions. The studies reported 
consistent recruitment parameters based on similar inclusion and exclusion criteria. 
Most studies stated that they were able to match the MS cases with a HC 
comparison group.  
 
2.4.8. Type of MS  
RRMS was the most commonly represented MS phenotype across the studies 
included in the review. The other disease courses represented to a lesser extent 
were SPMS, RPMS, PPMS and CIS. Most studies included a mix of phenotypes in the 
MS sample, while three included only RRMS. In the studies that mixed subtypes, 
there were different numbers of representations for each phenotype. 
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2.4.9. Disease duration and time since diagnosis  
The average disease duration varied between studies from 6.07 years (sd= 5.08) to 
12.97 years (sd= 7.16). 
  
2.4.10. BICAMS type and mode of delivery 
The conventional paper version of the BICAMS was used in all studies. As detailed in 
the study summary descriptions below, the BICAMS demonstrates good reliability 
and ability to distinguish individuals with MS from HC controls, as estimates of 
cognitive impairment were detected in almost half of individuals with MS. 
Appropriate translations were made to the BICAMS and were validated as part of the 
international validation protocol. Three studies reported the profession of the 
BICAMS assessor, which included a neuropsychologist, an MS Nurse Specialist and a 
PhD Student. Most studies did not report who administered the BICAMS. 
 
2.4.11. Individual study summaries 
A short description of each study which was included in the systematic review is 
provided below, with the first author’s name as reference to the paper.   
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Costers et al. (2017) 
The aim of the study was to validate the BICAMS in a Belgian Dutch-speaking 
population and to investigate the validity of including extensive versions of two of 
the three BICAMS subtests. Ninety-seven MS patients were recruited from National 
MS Center Melsbroek and the Revalidation and MS Center Overpelt in Belgium. 
Exclusion criteria were a relapse in the last month before assessment, neurological 
screening in the last three months before the assessment, neurological disorders 
other than MS that influence cognitive functioning (e.g. dementia or brain injury), 
psychiatric disorders, that could influence cognitive performance or  sensory or 
motor problems that could influence cognitive test performance. Ninety-seven 
healthy controls that were matched on age, education level and gender were 
recruited from friends or relatives of MS participants and from the personnel at the 
MS Center Melsbroek. Participants completed the SDMT and the full versions of the 
CVLT and BVMT-R, as well as the Beck Depression Inventory (BDI) (Beck, Ward, 
Mendelson, Mock & Erbaugh, 1961) and the Fatigue Scale for Motor and Cognitive 
Functions (FSMC) (Penner et al., 2009). A Dutch translation of the CVLT-II word list 
had been applied. Most of the sample had RRMS (84%). The results showed that only 
the SDMT and BVMT-R significantly distinguished individuals with MS from HC. MS 
performance on the CVLT-II indicated learning effects. They concluded that the 
extended versions of the CVLT-II and BVMT-R did not improve the psychometric 
properties of the BICAMS. Adults with MS were significantly more depressed than 
HC.  
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Dusankova, Kalincik, Havrdova & Benedict (2012) 
The objectives defined in this study were to test validity of the Czech translations of 
the MACFIMS and the BICAMS and to compare outcomes of the BICAMS to the 
Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS) (Benedict 
et al., 2006) in a sample of Czech individuals with MS. A large sample of 367 patients 
were recruited from the MS Centre of the General University Hospital and the first 
Faculty of Medicine, Charles University in Prague and 134 healthy controls were also 
recruited. Exclusion criteria were defined as: current or previous neurological 
disorder other than MS, a, prior history of a psychotic disorder, a current psychiatric 
disorder, other than mood, personality, or behaviour changes following the onset of 
MS, a medical condition which influences cognition, a history of a developmental 
disorder, a history of or current substance or alcohol dependence, a motor or 
sensory defect that might interfere with cognitive test performance, or a relapse 
and/or corticosteroid pulse within 4 weeks of assessment. All participants completed 
the SDMT and the full versions of the CVLT and BVMT-R, as well as the MACFIMS, 
BDI and BAI (Beck et al., 1961). The BICAMS was sensitive to detect cognitive 
impairment in MS defined by the MACFIMS. Cognitive impairment was found to be 
associated with vocational status. Individuals with MS showed high levels of anxiety 
and depression compared to health controls. 
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Eshaghi et al. (2012) 
The aim of this study was to validate Minimal Assessment of Cognitive Function in 
MS (MACFIMS) (Benedict et al., 2006) in Persian. There were 156 patients with MS 
who participated who had been receiving care in the MS Clinic at Sina Hospital in 
Tehran. Inclusion criteria for the study were for a diagnosis of MS by the revised 
McDonald criteria (Polman et al., 2005), the absence of neurologic/psychiatric 
diagnosis other than MS and MS-related behavioural changes, no IV corticosteroid 
use or MS relapse within six weeks of assessment, no history of a developmental 
disorder and no history of drug or alcohol substance abuse. The majority of the 
sample had RRMS (81%). Ninety matched for age, gender and education with 
healthy controls recruited from the community. All participants completed the SDMT 
and the full versions of the CVLT and BVMT-R as part of the complete MACFIMS. A 
subset of 41 patients completed the MACFIMS 10 days later for reliability analysis. 
The findings demonstrated that individuals with MS performed worse than HC on all 
aspects of the MACFIMS. The SDMT was identified as the most robust assessment. 
There were modest test re-test associations. 
 
Giedraitienė & Kizlaitienė (2015) 
The main objective of this study was to validate the Lithuanian translation of the 
BICAMS and to evaluate the test-retest reliability, and to estimate the impact of 
cognitive impairment on disability and duration of MS. Fifty patients with MS were 
recruited from Vilnius University Hospital Santariskiu Clinics. The inclusion criteria 
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specified that individuals with MS had a diagnosis based on the revised McDonald 
criteria (Polman et al., 2011) with no evidence of relapse for at least four weeks 
preceding participation in the study, no neurological or psychiatric disorder other 
than MS, no history of a developmental disorder, or visual or hearing problem which 
would confound performance on the battery, no cognition-enhancing medication 
(e.g., antidepressants, neuroleptics, and anticholinergic drugs) within the six months 
prior to taking part in the study and no current or past substance abuse. A total of 
twenty healthy control participants who were either the relatives of, and persons 
accompanying, the patients attending the Neurology Department were matched for 
age, gender and years of education. The majority of MS clinical cases had RRMS 
(88%). All participants completed the BICAMS Lithuanian translation. The results 
from the BICAMS show that individuals with MS scored significantly lower on all 
three subscales. The Lithuanian translation of the BICAMS had high test re-test 
reliability. Gender was not found to influence cognitive performance on the BICAMS. 
Years of education was found to significantly influence cognitive performance.  
 
Goretti et al. (2014) 
The objective of this study was to gather regression based normative data for the 
BICAMS battery in an Italian population. A large sample of 273 healthy controls was 
recruited from the community. The following exclusion criteria were applied: no 
history of a learning disability, or serious head trauma (causing coma and/or 
neuropsychological dysfunctions) and no history of alcohol or drug abuse as well as 
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major medical illness. The healthy sample completed the BICAMS Italian translation 
and at follow-up. A subset of 243 healthy controls participated in a follow-up 
assessment three weeks later. In the current study normative values with an Italian 
population were obtained.   
 
Niccolai et al. (2015)  
The main aim of this investigation was to compare the performance of BICAMS and 
Brief Repeatable Battery (BRB) (Rao & Cognitive Function Study Group & Society, 
1990) in MS subjects. A large sample of 192 patients with RRMS subtype was 
recruited from 11 Italian centres. Exclusion criteria specific was current or past 
neurological disorder other than MS, major psychiatric illness, a history of a 
developmental disorder, a head trauma, a history of alcohol or substance abuse or a 
relapse and/or corticosteroid use in the previous 4 weeks. Participants completed 
both the BRB and the Italian translation of the BICAMS. Cognitive performance on 
the BICAMS and BRB was compared to that of normative health controls in Goretti’s 
investigation (Goretti et al., 2014). Patients with RRMS had worse cognitive 
performance than the normative sample on both measures. There was a fair to 
moderate agreement between the BICAMS and the BRB on ability to distinguish HC 
from patients with MS, the SDMT was identified to be the strongest ability to 
indicate this difference. 
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Niino et al. (2018) 
The aim of the study was to validate and assess the reliability of the BICAMS in the 
Japanese population. A sample of 156 patients with MS were recruited according to 
the revised McDonald criteria (Polman et al., 2011). One hundred and twenty six 
healthy controls were matched for age, gender and duration of education. Exclusion 
criteria were severe visual or motor disabilities, neuromyelitis optica spectrum 
disorders (NMOSD), significant relapses or the use of steroids within 1 month before 
the examination and no previous major psychiatric disorder or prescribed anti-
psychotics. Most of the patients with MS had RRMS subtype (n=137). All participants 
completed the BICAMS Japanese translation. The findings showed that individuals 
with MS performed worse than healthy controls, particularly in the SDMT. Age at 
examination negatively correlated with cognitive performance on the BICAMS. 
Negative associations were recorded between educational level and the SDMT and 
CVLT-II subscales. 
 
O’Connell et al. (2015) 
The primary objective of this study was to validate the BICAMS in Irish patients with 
MS and healthy controls. Sixty-seven patients with MS according to the revised 
McDonald criteria (Polman et al., 2011) were recruited from a specialist clinic in a 
tertiary referral centre. Exclusion criteria were set as the following: a history of a 
neurological or psychiatric disorder, a concurrent medical condition that might 
influence cognition, a developmental disorder, a history of substance or alcohol 
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dependence, a visual, motor or sensory impairment that might interfere with 
cognitive test and a relapse or corticosteroid treatment within 4 weeks of taking part 
in the study. Sixty-six healthy control participants were recruited from unaffected 
relatives, spouses or carers and were matched by age, gender and years of 
education. Participants completed the BICAMS, Hospital Anxiety and Depression 
Score (HADS) (Zigmond & Snaith, 1983) and the Modified Fatigue Impact Scale 
(MFIS) (Fisk, Pontefract, Ritvo, Archibald, & Murray, 1994). Patients with MS had 
higher rates of unemployment. The BICAMS was shown to discriminate patients with 
MS from HC in the current study.  
 
Ozakbas et al. (2017) 
The purpose of this study was to validate the BICAMS in a Turkish population. One 
hundred and seventy-three MS patients were recruited according to the 2010 
revised McDonald criteria (Polman et al., 2011). The study applied the following 
exclusion criteria: no evidence of relapse, being steroid and/or plasmapheresis-free 
for at least 4 weeks, a history of a neurological disorder other than MS, a current 
psychiatric illness unrelated to that diagnosis, a coexistent medical condition, a 
history of developmental disorder, any vision or hearing problems and a history of 
alcohol or drug abuse. A total of one hundred and fifty three control participants, 
who were matched in terms of age, gender and years of education, were recruited 
from unaffected relatives or friends of MS patients or from other individuals 
attending the neurology outpatient clinic for other reasons. Participants completed 
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the BICAMS Turkish translation, the BDI (Beck et al., 1961), Modified Fatigue Impact 
Scale (MFIS) (Fisk et al., 1994) and the Multiple Sclerosis International Quality of Life 
(MUSIQoL) questionnaire (Simeoni et al., 2008). The BICAMS was repeated. Most the 
MS sample had RRMS (87%). The results from the BICAMS showed that MS patients 
performed significantly worse on all subsets compared to healthy controls. Cognitive 
impairment was demonstrated in 45% of patients. The BICAMS showed strong test 
re-test reliability. Disability and duration of disease was associated with severity of 
cognitive impairment.  
 
Polychroniadou et al. (2016)  
The objective of this study was to validate the BICAMS in a Greek population. Forty 
four patients with MS were recruited according to the revised MacDonald criteria 
(Polman et al., 2011), including those with Clinically Isolated Syndrome (CIS). Patients 
were included regardless of Disease Modifying Treatment (DMT) or a history of a 
major psychiatric illness. Seventy healthy controls were matched according to age, 
education, gender and premorbid cognitive reserve. All participants completed the 
Greek adaptation of the BICAMS and Cognitive Reserve Index questionnaire (CRIq) 
(Nucci, Mapelli, & Mondini, 2012) and again at follow-up. The findings showed that 
individuals with MS performed significantly worse than healthy controls. According 
to the BICAMS, 47% met the criteria for a cognitive impairment. Test re-test 
reliability was strong.  
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Sandi et al. (2015)  
The aim of this study was to assess the validity of the BICAMS Hungarian translation 
and to evaluate this in relation to quality of life and its impact on cognitive status. 
Sixty-five patients with MS were recruited from the Department of Neurology of the 
University of Szeged. A comparison group of sixty-five HC were recruited and were 
matched for age, sex and years of education. All individuals with MS had RRMS 
subtype. Exclusion criteria were for acute relapse, alcohol abuse and a history of a 
psychiatric, mood or personality disorder. All participants completed the BICAMS 
Hungarian translation and at follow-up, the Fatigue Impact Scale(FIS)(Fisk et al., 
1994) and the Multiple Sclerosis Quality of Life-54 (MSQoL54) (Fuvesi et al., 2008; 
Vickrey, Hays, Harooni, Myers, & Ellison, 1995). The results showed that individuals 
with MS performed significantly worse than healthy controls, apart from the CVLT-II 
immediate test. There was a modest test re-test correlation on BICAMS 
performance. 52% of individuals with MS were shown to have a cognitive 
impairment. Fatigue negatively correlated with cognitive performance. Cognitive 
impairment was adversely associated with several domains of quality of life, 
including physical functioning, social and cognitive functioning, general health scale, 
quality of life and sexual performance and satisfaction with sexual performance. 
 
Spedo et al. (2015)  
The primary objective of this investigation was to assess the validity of the BICAMS 
Brazilian-Portuguese translation. Fifty-eight MS patients were recruited from MS 
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Centres in Brazil and fifty-eight healthy controls were recruited from the community 
were matched on several demographic characteristics. All participants were free 
from a history of a neurological disease other than MS, had no prior psychiatric 
illness or depression emerging after the development of MS or history of substance 
or alcohol dependence. All MS patients had RRMS subtype and diagnosis of MS was 
based on the revised McDonald criteria (Polman et al., 2011). Individuals with MS 
had no acute relapse within the past 30 days. Participants completed the BICAMS 
Portuguese translation at two times, one at baseline and one at two weeks follow-
up, as well as the Hospital Anxiety and Depression Scale (Herrmann, 1997). The 
findings showed that individuals with MS had significantly poorer cognitive 
performance on the BICAMS compared to healthy controls and this effect still stood 
even after the effects of depression, anxiety, education and age were removed. Test 
re-test associations ranged between good to excellent. Individuals with MS had 
higher rates of depression, but not anxiety, compared to healthy controls. Age 
negatively correlated with all BICAMS subscales whereas education was positively 
correlated with the performance on the instrument. 
 
Strober et al. (2009) 
The aim of this study was to examine the sensitivity of BRNB (Rao, 1991) and 
MACFIMS (Benedict et al., 2006) batteries in MS and to understand which measures 
best discriminate MS patients from healthy controls. This study was included in the 
review as it uses the BICAMS subscales. A total of sixty-five patients from the United 
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States were recruited to participate in the study. Forty-six health controls were 
matched for age and education. Exclusion criteria included a history of a neurological 
or psychiatric disorder other than MS, a current depressive episode, a history of a 
developmental disorder, a history of substance dependence, a motor or sensory 
defect that might substantially interfere with cognitive test performance or an acute 
relapse within 4 weeks of assessment. The majority of MS patients had RRMS (72%). 
Participants completed all aspects of the BRNB (Rao, 1991) and MACFIMS (Benedict 
et al., 2006) batteries, which included the SDMT, CVLT-II and BVMT-R. Participants 
with MS were shown to perform significantly worse on the SDMT and BVMT-R 
compared to healthy controls. Their complete performance on the CVLT-II did not 
discriminate them from healthy controls, patients with MS only performed 
significantly worse than healthy controls on the immediate delayed recall aspects of 
the test, but had similar performance on sematic and serial clustering. The MACFIMS 
was found to a have marginally better ability to discriminate individuals with MS 
from healthy controls (83%) compared to the BRNB (79%).  
 
Vanotti et al. (2016) 
The aim of this study was to validate the BICAMS in Argentina and to obtain 
normative data in Spanish for this population. Fifty participants with MS were 
recruited for the study. Diagnosis was made according to the revised McDonald 
criteria (Polman et al., 2011). The majority of the sample had RRMS subtype (78%). 
One-hundred healthy control participants were recruited from the community and 
 
 
63 
 
were matched in terms of age, years of schooling and gender. Elusion criteria 
included the following: current or previous neurological disorder other than MS, 
history of psychotic or psychiatric disorder, a medical condition that might affect 
cognition, a history of developmental disorder, a history of substance or alcohol 
abuse, motor or sensory disability, an acute relapse and/or corticosteroid pulse in 
the previous four weeks of assessment. Healthy controls were required to score 
above 26 points on the Folstein Mini-Mental State Examination (MMSE) (Butman et 
al., 2001) and less than 14 on the BDI-II (Beck, Steer, & Brown, 2006) and have no 
history of neurological disease. The BICAMS Spanish translation was administered to 
all participants and at follow-up as well as the MS Functional Composite (MSFC) 
(Fischer, Rudick & Cutter, 1999), Paced Auditory Serial Addition Test (PASAT) (Cutter 
et al., 1999) and Expanded Disability Status Score (Kurtzke, 1983). The individuals 
with MS performed significantly worse than the HC group on the three 
neuropsychological tests, included the BICAMS. Test re-test reliability was found to 
be excellent. 
 
Vanotti et al. (2017)  
The aim of this study was to examine performance on the BICAMS compared to 
clinical characteristics, perceived cognitive difficulties and key employment variables. 
The same sample of fifty participants as the other Vanotti paper with MS were 
recruited for the study and the inclusion criteria for these has been described above. 
Diagnosis was made according to the revised McDonald criteria (Polman et al., 
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2011). Participants completed the BICAMS Spanish translation, the Multiple Sclerosis 
Neuropsychological Questionnaire (MSNQ)(Benedict et al., 2004), the Expanded 
Disability Status Score (EDSS) (Kurtzke, 1983), the Paced Auditory Serial Addition Test 
(PASAT) (Cutter et al., 1999), the Beck Depression Inventory (BDI-II) (Beck et al., 
2006) and the Fatigue Severity Scale (FSS) (Krupp, Alvarez, LaRocca, & Scheinberg, 
1988). The results showed that disease progression and employment were most 
strongly correlated with cognitive performance on the BICAMS test. Gender, years of 
education and patient reported cognitive status were not found to be predictive of 
cognitive performance.  
 
Walker et al. (2016) 
The objective of the study was to validate the BICAMS in a Canadian population and 
to examine if self-reported cognition predicted vocational status. Fifty-seven 
individuals with MS were recruited from the Ottawa Hospital for MS. Fifty-one 
healthy controls were recruited from the community or were friends or family 
members (not first degree relative) and were matched on age, gender and 
education. Exclusion criteria included any neurological, medical, or psychiatric 
conditions including head trauma, developmental difficulty, a history of seizures, 
uncorrected visual acuity problems, corticosteroid or immunosuppressive treatment 
within two months of inclusion in the study, a current MS relapse and a history of 
drug dependence. Participants completed the BICAMS battery and at follow-up, as 
well as the Patient Health Questionnaire (PHQ-9) (LÖwe, UnÜtzer, Callahan, Perkins, 
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& Kroenke, 2004). The results showed that adults with MS had significantly higher 
levels of depression and fatigue. Participants with MS performed significantly worse 
than healthy controls at baseline and at follow-up according to the SDMT and the 
BVMT-R. However no group differences were observed in CVLT-II performance 
between the groups after accounting for the effects of depression and fatigue. Over 
half of the sample were identified to have a cognitive impairment (57.9%). The 
BICAMS had good test-retest reliability, especially with scores on the SDMT. There 
was no statistically significant association between the BICAMS variables and 
subjective cognition. The only BICAMS subscale found to reliably predicted 
employment to a significant degree was the BVMT-R. 
 
2.4.12. Meta-Analysis of BICAMS validation studies  
The results from all three subscales of the BICAMS, which are SDMT, CVLT-II and 
BVMT-R, showed that adults with MS performed significantly worse than controls 
across all three cognitive domains.  
 
2.4.13. Symbols Digit Modalities Test (SDMT) 
The forest plot presented in Figure 2 shows the effect size for each study which 
tested the SDMT in MS cases and controls. The analysis showed that overall 
information processing speed was significantly reduced in adults with MS compared 
to HC, with a large effect size (g = 0.943, 95% CI = 0.839, 1.046, p < .001). The 
 
 
66 
 
sensitivity analyses found no evidence of outliers, heterogeneity (Q = 20.66, p > .05) 
or publication bias present (Egger’s test = p > .050, 2-tailed). The associated funnel 
plot (see Appendix) shows that the effect sizes were symmetrical. As a result the trim 
and fill analysis (Duval & Tweedie, 2000) estimated that there were 0 missing studies 
from the analysis. 
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Note. Healthy Control (HC); Multiple Sclerosis (MS).  
Figure 2. Forest plot for the Symbol Digit Modalities Test (SDMT). 
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2.4.14. California Verbal Learning Trials (CVLT-II)  
Figure 3 displays the forest plot of effect sizes for each study which compared CVLT-II 
performance between MS cases and controls. Overall immediate verbal recall was 
significantly lower in individuals with MS compared to HC, with a medium effect size 
(g = 0.688, 95% CI = 0.554, 0.822, p < .001). The sensitivity analyses showed that 
while there was no evidence of outliers, heterogeneity was indicated (Q = 36.04, p < 
.001) to a moderate extent (I2 = 63.94). The Trim and Fill method indicated that only 
one study would be required to fall on the left of the mean effect size to make the 
plot symmetrical (see Appendix). Therefore, with the addition of the single imputed 
study, the adjusted effect size remained medium (g = 0.671, 95% CI = 0.539, 0.804). 
Egger’s test was non-significant (p = .750, 2-tailed) indicating that there was no 
evidence of publication bias.  
 
2.4.15. Brief Visual Memory Test Revised (BVMT-R) 
The forest plot presented in Figure 4 show the effect sizes for the studies which 
tested MS performance on the BVMT-R with that of HC. The meta-analysis showed 
that overall immediate recall of visual memory was reduced in adults with MS 
compared to HC, with a medium effect size (g = 0.635, 95% CI = 0.534, 0.736, p < 
.001). Formal sensitivity analyses showed that there was no evidence of outliers or 
heterogeneity (Q = 20.727, p > .05). The funnel plot presented in the Appendix 
demonstrates that the effect sizes were symmetrical. Thus the trim and fill analysis 
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estimated that there were 0 missing studies from the analysis. Egger’s test (p = .781) 
indicated that there was no evidence of publication bias.  
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Note. Healthy Controls (HC); MS (Multiple Sclerosis).  
Figure 3. Forest plot for California Verbal Learning Trials II (CVLT-II). 
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Note. MS (Multiple Sclerosis); HC (Healthy Controls).  
Figure 4. Forest plot for the Brief Visual Memory Test Revised (BVMT-R). 
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2.5. Discussion 
2.5.1. Summary of Findings 
The aim of the review was to synthesise the studies produced as part of the 
international validation of the BICAMS through conducting a systematic review and 
meta-analysis. Sixteen studies were included into the systematic review. Of those 
identified, 14 articles met the additional criteria to be included in a meta-analysis.  
The results from the systematic review showed that the BICAMS international 
validation protocol had been embraced and adhered to by many different countries, 
as demonstrated by its broad validation across different languages, cultures and 
locations. The brief tool for assessing cognition in MS was applied to cases with 
different MS disease courses, durations and severity. Most studies reported 
attempts to include a matched HC group. The occupation of the BICAMS examiner 
was underreported in most studies; however this detail has important implications, 
since the BICAMS is purported to be able to be administered by most healthcare 
professionals.  
Adults with MS consistently showed difficulties with cognition compared to the HC 
across three individual meta-analyses. Cognitive impairment was most prevalent in 
IPS, followed by immediate verbal and visual recall. This is not the first study to 
demonstrate that cognitive difficulties arise in MS. The results of the current review 
are in line with the established knowledge and view of earlier literature, which 
demonstrate IPS is significantly reduced in MS (Costa et al., 2016). There is an 
emerging evidence base focused on the profile of cognitive impairment in MS. 
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Recent taxonomies have been proposed, which categorise ~7% of individuals with 
MS with impaired IPS, ~18% with memory impairment, ~17% with IPS and memory 
impairment, while the remaining 50% are not cognitively impaired (Leavitt, Tosto, & 
Riley, 2018). The current meta-analysis is unable to confirm the suggested 
taxonomies. However from the results there is a strong argument for IPS being the 
primary cognitive deficit in MS. This current review adds to the existing reviews 
which have shown differences in cognition between people with MS and controls in 
a number of ways. Firstly it allows for comparison of performance between 
individuals from the same country, as opposed to US norms (Benedict et al., 2012). 
Secondly it evaluates a standardised tool which assesses the three most prevalent 
areas of cognitive impairment which were decided by an expert consensus. Thirdly 
the inclusion of the meta-analysis was able to investigate consistency in cognitive 
performance across the validation studies. 
 
2.5.2. Beyond validation studies 
BICAMS has been investigated beyond the validation studies. While the primary 
focus of this systematic review was on those articles within the international 
protocol, it is important to recognise the wider context. Studies outside the 
international validation examine how BICAMS relates to personal factors, brain 
structure and treatments. Several socio-demographic and health factors were 
related to at least one impairment on a BICAMS subscale. They included older age, 
lower education, higher EDSS and male gender (Sacca et al., 2016). An MRI study 
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showed that low brain parenchymal fraction (BPF) and high T2 lesion volume (T2-LV) 
were associated with cognitive impairment on the BICAMS (Uher et al., 2017).  
BICAMS has been applied to examine the impact of a range of treatments. Remote 
telephone assessment of the CVLT-II was found to yield similar results to in person 
administration (Barcellos et al., 2017). Visuospatial memory improved in people with 
MS who took betula papyrifera, a resinous extract, twice daily (Sedighi, Pardakhty, 
Kamali, Shafiee, & Hasani, 2014). Performance on the SDMT subscale of the BICAMS 
improved greatly over a six week home-based computerised assessment (Campbell, 
Langdon, Cercignani, & Rashid, 2016). The BICAMS battery was used to explore the 
efficacy of DMDs (Cinar, Kösehasanoğulları, Yigit, & Ozakbas, 2017). 
 
2.5.3. Impact on quality of life  
Cognitive impairment has a major negative impact on quality of life, including 
financial situation, which is independent of physical disability (Kavaliunas et al., 
2017). Better BICAMS performance is related to more independent activities of daily 
living (Goverover, Chiaravalloti, & DeLuca, 2016). BICAMS is significantly correlated 
with the Expanded Disability Status Scale (EDSS), which measures MS disability 
(Kurtzke, 1983). The SDMT is a strong predictor of functional decline in work status 
(Benedict et al., 2016) and unemployment (Campbell, Rashid, Cercignani, & Langdon, 
2016). Impaired SDMT, in particular, predicts poor health related quality of life 
(Hoogs, Kaur, Smerbeck, Weinstock-Guttman, & Benedict, 2011) and also impacts on 
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caregivers' quality of life (Labiano-Fontcuberta, Mitchell, Moreno-García, & Benito-
León, 2014).  
 
2.5.4. Strengths 
The current review has a number of strengths to highlight, particularly related to the 
acceptability and feasibility of the BICAMS. The countries which participated in the 
international validation protocol agreed that the BICAMS could be administered and 
completed easily in under 15 minutes with minimal materials. There was a wide 
representation of cultures, languages and locations involved in the international 
protocol initiative. This has been quantified by comparison of the sample sizes per 
study against the number of those reported with MS in each country according to 
the Atlas of MS tool (Browne et al., 2014). The greatest representation of adults with 
MS in the current review was from Lithuania.  
The BICAMS was validated within three English speaking countries as part of the 
international validation protocol (USA, Canada and Ireland). It is important to note 
here the necessity of this undertaking, as there is a distinction between language 
and culture. The cultural norms of these specific populations are markedly different 
and this is likely to interfere with the reliability of cognitive testing (e.g. Chevalier, 
Stewart, Nelson, McInerney, & Brodie, 2016). Further nationality significantly 
predicts performance all BICAMS subscales, even after adjusting for age and years of 
education (Smerbeck et al., 2017). The gender ratio observed in validation studies 
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are in line with the disease representation. MS disproportionally impacts more 
women than men (Boström & Landtblom, 2015).  
This review is a significant first step in accumulating objective scores of cognitive 
ability in individuals with MS compared to matched HC in a brief, standardised 
manner. The direction of the results was as expected, as indicated by previous 
research studies on all three scales. It is important to consider that the CVLT-II scores 
were more heterogeneous than other subscales, possibly relating to the extra 
linguistic and cultural demands of the stimuli. This is important as cultural norms of 
populations are markedly different (e.g. Chevalier et al., 2016). The SDMT 
(infomraiton processing speed) and BVMT-R (immediate visual recall) are less 
linguistically or culturally loaded compared to the CVLT-II (immediate auditory verbal 
recall) and thus are less likely to be influenced by translation. For example, difficulty 
translating the CVLT-II was reported in one validation study (Costers et al., 2017). 
This is demonstrated in the their finding that MS cases and controls had similar 
scores on the CVLT-II (see Figure 3).  
 
2.5.5. Limitations 
This review has a number of limitations. Firstly, in relation to the strategy adopted. 
The choice of search terms may have been too constrictive, since there are 
additional ways to describe MS (e.g. autoimmune disorder, degenerative condition) 
which, if applied to the terms, could have improved the sensitivity of the search. The 
omission of searching reference lists and screening citing papers could have further 
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limited the breadth of the search, so that the number of those returned using the 
current strategy could have been an underestimate. The identification of three 
studies through expert opinion may be associated with the limitations with 
selectivity and sensitivity described above. It will be important for future reviews to 
adopt a more comprehensive search strategy after taking into consideration the 
points from these steps. The inclusion of Strober et al. (2009) was necessary as it 
includes the BICAMS subscales. Yet since it was published prior to the formal BICAMS 
recommendations (Langdon et al., 2012) then its design may differ from the 
international criteria outlined (Benedict et al., 2012). It will be important to consider 
this distinction when evaluating this study with others participating in the 
international validation process. 
Secondly, in terms of sampling, there was a great deal of heterogeneity between the 
sample sizes and MS phenotypes. In particular this would have had an impact on the 
weights for each study in the meta-analysis. The disproportionate representation of 
each MS phenotype may have influenced the degree of the effect size, as cognitive 
impairment is more common in progressive forms of the disease. Thus, while RRMS 
was overrepresented in studies, which is consistent with prevalence rates, it may 
have impacted upon the effect sizes observed.  The HC were recruited from the 
community or were related or known to the adult with MS. In the instance where HC 
were related to the adult with MS, then this would pose a threat to the statistical 
assumption of independence between the samples examined. It is important to 
consider the average age of those tested in the current review and that the degree 
of cognitive impairments identified by the BICAMS is likely to be negatively skewed, 
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as the range of duration of illness was over 6 years. There are issues around not 
controlling for the effects of comorbidity and medication on cognitive performance 
in the studies.  
Thirdly, important relationships between cognitive impairment and moderators 
could not be explored in the current review. The current study was unable to 
perform meta-regressions to explore associations between specific cognitive 
impairment, disease subtype, duration, age and education. Although with future 
BICAMS validation studies are to be published imminently and it is likely that 
subsequent reviews will be able to draw more robust conclusions related to these 
lines of interest. Further to this point, few studies included accompanying 
neurocognitive assessments which examine additional cognitive domains. While it is 
beyond the scope of the current review to examine all aspects of cognition in MS, 
further investigations are required for attentional aspects, executive functioning and 
cognitive flexibility. 
Fourthly, the quality of studies was rated relatively poorly according to the EPHPP. It 
is interesting to note that high quality validation studies were rated as ‘Weak’ on 
several dimensions (e.g. ‘Blinding’ and ‘Data Collection Method’). This outcome is 
likely to be explained by the parameters which are usually applied to general studies 
not coinciding with the requirements for stringent international validation. This was 
evidenced by the polarity in scoring, since other dimensions were rated more 
strongly (‘Selection Bias’ and ‘Study Design’). Therefore using the EPHPP to assess 
the quality of validation studies is likely to be unsatisfactory for this reason. 
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2.5.6. Recommendations 
A follow-up review will be necessary once all partaking countries have published 
their findings. This current systematic review only provides an interim picture of the 
international validation of the BICAMS endeavour. Many countries have not yet 
published their data. Thus a subsequent review will provide a more comprehensive 
understanding of the international validation undertaking.  
As the BICAMS is intended to be used as a screening tool to monitor cognitive ability 
it will be important to implement longitudinal study designs to establish scale 
reliability. As well as supporting understanding about cognitive profiles in RRMS and 
their trajectory, this may ascertain the predictive validity of the scale. BICAMS could 
be used alongside MRI techniques to support with the identification of biomarkers 
for cognitive impairment. 
Understanding how the BICAMS relates to intervention for cognitive impairment is of 
high importance. Although clinical cut-offs have been proposed (Beier et al., 2017), 
there are no current thresholds for BICAMS scores. In the subsequent review it may 
be necessary to revisit this aspect to refine cognitive assessment. With this in mind it 
will be crucial to include BICAMS in research to examine efficacy of treatment. 
 
2.5.7. Conclusions 
The BICAMS has demonstrated good validity to measure cognition in MS at an 
international standard. It is able to distinguish cognitive impairment in individuals 
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with MS compared to controls across a variety of cultures, languages and locations. 
The international MS community has participated in the international validation 
protocol to great success. This is an important step in optimisation of cognitive 
assessment and supports with its inclusion into routine clinical appointments. The 
MS community has acknowledged cognitive impairment in MS as a significant issue. 
Studies underway which are yet to be published are expected to further improve the 
specificity of the BICAMS.  
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3. Empirical Study 
Validation of the iPad Brief International Cognitive Assessment for Multiple 
Sclerosis (BICAMS) 
 
3.1. Abstract 
Half of those with multiple sclerosis (MS) will experience cognitive impairment. The 
Brief Cognitive Assessment for Multiple Sclerosis (BICAMS) was designed to assess 
the three most common cognitive impairments. iPad BICAMS was developed in early 
2018 and could offer the added benefits of automated presentation times and 
scoring. 
The aim of the study is to confirm the level of agreement between the iPad BICAMS 
and the paper and pencil form. Forty people with MS (27 females, mean age: 45, 32 
RRMS) completed the following battery: (a) cognition was tested using the iPad and 
paper BICAMS (Symbol Digit Modalities Test, SDMT; California Verbal Learning Trials 
II, CVLT-II; Brief Verbal Memory Test Revised, BVMT-R); (b) premorbid functioning 
was assessed using the Test of Premorbid Functioning (TOPF); (c) dexterity was 
tested using the Nine Hole Peg Test (9HPT) and the Grooved Peg Test (GPT); (d) 
visual functioning was examined using the Multiple Sclerosis Vision Test Batter 
(MSVTB); (e) mood and anxiety was tested using the Hospital Anxiety and Depression 
Scale (HADS); (f) fatigue was assessed using the Fatigue Severity Scale (FSS) and; (g) a 
short survey captured participants’ experience of BICAMS.  
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The iPad BICAMS showed above satisfactory level of agreement across three 
intraclass correlations, particularly so for SDMT (.85, 95% CI (0.74, 0.92), p < .001), 
followed by BVMT-R (.67, 95% CI (0.45, 0.62), p < .001) and CVLT-II (.57, 95% CI (0.32, 
0.75), p < .001). 9HPT, GPT, HADS and high contrast visual acuity were within the 
mild ranges. Low contrast visual acuity and letter contrast sensitivity was in the 
impaired range. There were no associations found between iPad BICAMS 
performance and TOPF, 9-HPT or FSS. However, SDMT was found to negatively 
correlate with motor planning (r = -.469, p =.002) and BVMT-R with high contrast 
visual acuity (r = -.459, p =.003). Seventy percent of participants reported that they 
would be ‘moderately’ to ‘very’ satisfied to be tested by the iPad BICAMS on a yearly 
basis in the future. 
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3.2. Introduction 
 
3.2.1. Multiple Sclerosis 
Cognitive impairment is quite common in Multiple Sclerosis (MS) (Benedict & 
Zivadinov, 2011). MS is a chronic autoimmune, inflammatory neurological disease of 
the central nervous system. The hallmarks of the condition are axonal or neuronal 
loss, demyelination and astrocytic gliosis (Thompson et al., 2018). Symptoms are a 
consequence of these neurological changes and they include cognitive, motor, 
sensory, visual, bowel and bladder dysfunctions (Lassmann, 2010).  
Diagnosis is based on the McDonald Criteria (Lublin et al., 2014). The prevalence of 
MS has increased greatly over the past decade (e.g. Rotstein et al., 2018). Close to 
127, 000 individuals in the United Kingdom have the condition (Mackenzie, Morant, 
Bloomfield, MacDonald, & O’Riordan, 2014). MS is one of the most common causes 
of neurological disability amongst young adults (Deloire, Ruet, Hamel, Bonnet, & 
Brochet, 2010; Ruet et al., 2013). There are higher rates of MS in women than in 
men (e.g. Westerlind et al., 2014).  
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3.2.2. Phenotypes 
Four MS individual disease courses have been distinguished (Achiron et al., 2012; 
Thompson et al., 2018):  
(a) Relapsing Remitting MS (RRMS): The most common form of MS includes 
at least one episode, which involves the optic nerve, brainstem or spinal cord;   
(b) Secondary-Progressive MS (SPMS): Between 15%-30% of individuals with 
RRMS will develop progressive disability, with or without superimposed 
relapses; 
(c) Primary Progressive MS (PPMS): Approximately 15% of people with MS 
experience a progressive form of MS from the outset; 
(d) Benign MS: Occurs in approximately 15% of individuals and until recently 
the disease course was not thought to involve significant neurological 
disability. 
 
3.2.3. Cognitive Impairment in Multiple Sclerosis   
Approximately 50% of people with MS have a cognitive impairment (Benedict & 
Zivadinov, 2011). It occurs across all phenotypes (Potagas et al., 2008). Cognitive 
impairment has been observed in older adulthood (Bollaert et al., 2017). It is most 
prevalent in progressive forms of the condition, however (Papathanasiou et al., 
2014). This is evident even after a decade of illness duration (Planche, Gibelin, 
Cregut, Pereira, & Clavelou, 2016). Cognitive impairment has been observed across 
several cognitive domains. 
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3.2.4. Information Processing Speed (IPS) in Multiple Sclerosis   
Information Processing Speed (IPS) refers to the amount of time required to process 
a set amount of information (Kalmar & Chiaravalloti, 2007). Prevalence rates of IPS 
impairments in MS is high and ranges between 20% – 50% (Grzegorski & Losy, 2017). 
Thus IPS is thought to represent the core cognitive difficulty in MS (Denney et al., 
2004), as it occurs simultaneously with impairments in other cognitive domains 
(Chiaravalloti & DeLuca, 2008). However, support for this argument remains 
tentative due to the heterogeneity of samples and study designs in the literature 
(Costa et al., 2016).  
 
3.2.5. Immediate Verbal Recall in Multiple Sclerosis   
Episodic memory is the second most typical cognitive dysfunction in MS, with 
estimated prevalence falling between 33% – 65% (Grzegorski & Losy, 2017). Two 
positions have emerged from the literature, surrounding whether difficulties in 
verbal recall relate to retrieval (e.g. Rao et al., 1984) or acquisition deficit (Demaree, 
Gaudino, DeLuca, & Ricker, 2000; Gaudino, Chiaravalloti, DeLuca, & Diamond, 2001). 
The debate continues today, as several published meta-analyses are unable to agree 
on a common understanding (Lafosse et al., 2013; Prakash et al., 2008; Thornton & 
Raz, 1997; Wishart & Sharpe, 1997; Zakzanis, 2000). 
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3.2.6. Immediate Visual Recall in Multiple Sclerosis   
Immediate visuospatial recall is defined as the recognition of visual information and 
the ability to evaluate that information (Chiaravalloti & DeLuca, 2008). This is 
thought to be the third most common cognitive impairment in MS (20% - 26%) 
(Vleugels et al., 2000). Visuospatial ability is relatively less understood than other 
cognitive domains but, as expected it is associated with primary visual problems. 
These difficulties could influence higher-order visual functions (Bruce et al., 2007). 
Visuoperceptual skills correlates with overall cognitive status and physical disability 
in MS (Vleugels et al., 2000).  
 
3.2.7. Other cognitive impairments in Multiple Sclerosis   
Attention, which refers to alertness and vigilance (Winkelmann, Engel, Apel, & Zettl, 
2007), is also impaired in MS. Prevalence estimates range between 12% – 25% 
(Grzegorski & Losy, 2017). Difficulties have been demonstrated across many 
different attentional paradigms (Adler & Lembach, 2015; Beatty et al., 1995; 
McCarthy et al., 2005). Executive function is defined as a combination of processes 
required for goal-directed behaviour (Chiaravalloti & DeLuca, 2008). Executive 
functioning skills are impaired in MS (Santiago et al., 2007). The prevalence rates of 
executive functioning difficulties have been reported between 7% - 19% (Grzegorski 
& Losy, 2017). 
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3.2.8. The impact of cognitive impairment in Multiple Sclerosis   
Most people with MS in the United Kingdom report experiencing cognitive 
impairment (72%) (Thompson et al., 2017). It is important to assess cognitive 
impairment as the literature suggests that it negatively impacts on quality of life, 
over and above the impact of physical impairments (Langdon, 2010). Participatory 
activities, including employability (Morrow et al., 2010), driving (Lincoln & Radford, 
2008) and leisure activities (Patel, Walker, & Feinstein, 2017) are all adversely 
influenced by cognitive impairment. Cognitive impairment also increases risk for falls 
(Gunn et al., 2013) and issues with drug adherence (Bruce et al., 2010).  
 
3.2.9. Therapeutic interventions in Multiple Sclerosis   
A variety of disease modifying dugs (DMD) ameliorate MS symptoms (Tsivgoulis et 
al., 2015), however at present there are none available to specifically target 
cognitive impairment (Benedict & Zivadinov, 2011). Specific cognitive training and 
holistic approaches are available to improve cognitive ability (Charvet et al., 2017; 
Mattioli et al., 2016). There is strong evidence to show that cognitive rehabilitation is 
effective up to six months following intervention (Chiaravalloti, Moore, Nikelshpur, & 
DeLuca, 2013). Thus cognitive assessment is vital to guide referral for targeted 
intervention. 
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3.2.10. Assessing cognition in Multiple Sclerosis   
There are no diagnostic criteria for cognitive impairment in MS (Thompson et al., 
2017). Until recently cognitive assessments were typically conducted exclusively in 
University Hospitals and Specialist MS Centres. Assessment can be challenging in 
clinical contexts for numerous reasons: firstly (a) Magnetic Resonance Imaging (MRI) 
is not precise enough to assess cognitive impairment (Rocca et al., 2015); secondly 
(b) clinical interview and standard neurological examination are not sufficiently 
sensitive to identify impairment in MS (Romero et al., 2015); and thirdly (c) self-
reported cognitive complaints are obscured by mood and other subjective symptoms 
(Carone, Benedict, Munschauer, Fishman, & Weinstock-Guttman, 2005). Thus, 
objective assessments of performance are needed. 
 
3.2.11. Neuropsychological assessments in Multiple Sclerosis   
Neuropsychological assessments contain standardised instructions, scoring criteria, 
normative data and psychometric properties and can be applied to assess a range of 
cognitive domains, including language, visual processing, memory, IPS, cognitive 
flexibility and executive functioning (Lezak, 1995). Cognitive domains such as IPS and 
anterograde episodic memory can be difficult to assess without neuropsychological 
testing (Rao, St Aubin-Faubert, & Leo, 1989). 
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Several brief assessments are available to screen for cognitive impairment in MS 
(e.g. Freitas et al., 2016; Hansen et al., 2015; Hansen et al., 2017). Yet they differ in 
their focus of assessment and definition of clinical thresholds for impairment. MS-
specific neuropsychological test batteries are sensitive to assess for cognitive 
impairment in the condition (e.g. Gromisch et al., 2016). The most commonly used of 
these is the Brief Repeatable Battery of Neuropsychological Tests (BRB) (Rao & 
Group, 1990) which takes approximately 45 minutes to administer. The BRB includes 
the Selective Reminding Test (verbal memory), the Symbol Digit Modality Task 
(SDMT; IPS), the Paced Auditory Serial Addition Test (PASAT; IPS), the 10/36 Spatial 
Memory Test, and Verbal Fluency (executive skills).  
The Minimal Assessment of Cognitive Function in MS (MACFIMS) (Benedict et al., 
2002; Guimarães & Maria José Sá, 2012) is a more comprehensive assessment of 
cognition in MS. MACFIMS takes 90 minutes to administer and includes SDMT for 
IPS, PASAT for IPS, D-KEFS Sorting Task (executive skills – flexibility), CVLT-II for 
verbal memory, BVMT-R for visual memory, Controlled Oral Word Association Test 
(COWAT) for language and the Judgement of Line Orientation (JLO) for spatial skills.  
 
3.2.12. Brief International Cognitive Assessment for Multiple Sclerosis 
There are several caveats to using neuropsychological batteries, which includes 
access resources and specialist training needs (e.g. Santos, Pinheiro & Barros, 2015). 
The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) 
(Langdon et al., 2012) was developed in 2010 as a brief screen of cognitive 
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impairment for small centres with limited neuropsychological expertise.  The BICAMS 
includes the (a) Symbol Digit Modalities Test (SDMT; (Smith, 1982); (b) California 
Verbal Learning Test II (CVLT-II; (Delis, 2000) learning trials; and (c) Brief Visual 
Memory Test - Revised (BVMT-R; Benedict, 1997) learning trials, which assess 
domains of IPS, immediate verbal and visual recall.  
The BICAMS assesses the most prevalent cognitive impairments in MS, which occur 
at any stage of the disease and within all phenotypes. BICAMS could be used to 
determine the predictive value of subsequent cognitive functioning (Bergendal, 
Fredrikson, & Almkvist, 2007) as well as monitoring DMD treatment (Cinar et al., 
2017). Several validation studies have been published and are underway as part of 
the international validation protocol. 
 
3.2.13. Computerised neuropsychological assessments 
Computerised cognitive batteries may overcome the difficulties with conventional 
assessment, including stimuli display times and automated scoring (Lapshin, 
Oconnor, Lanctt, & Feinstein, 2012). iPad BICAMS is arguably the next step in 
cognitive assessment in MS. The physical (visual and auditory) parameters of the 
tests have been kept constant with the paper version. iPad BICAMS runs on two 
iPads, with individual software for the examiner and the participant versions. The 
written instructions for the investigator have been amended from the paper manual 
to accommodate the iPad format. The iPad BICAMS improves validity and efficiency 
of testing by evaluating whether the participant has sufficient visual acuity and 
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manual dexterity to proceed with the exam, controlling exposure time of BVMT-R 
and automatic scoring of SDMT and CVLT-II trials. As well as meeting patient 
expectations, making iPad BICAMS scores digital is necessary to coincide with 
Electronic Health Records (EHR). 
Cognitive assessments for iPads have been developed and validated in other 
neurodegenerative conditions. For example the Cognitive Assessment for Dementia 
(CADi) has been validated in individuals with dementia with acceptable Cronbach’s 
alpha values (over 0.7) and test-retest reliability at one-year (Onoda et al., 2013). 
Similarly the Computerized Cognitive Composite for Preclinical Alzheimer’s Disease 
(C3-PAD) has shown excellent validity (0.93) compared to home versus clinic 
cognitive performance (Rentz et al., 2016).  
 
3.2.14. Factors associated with cognitive ability 
There are various methods of assessing cognition in MS, which have been described 
above. When evaluating cognitive ability it is important to consider wider contextual 
interpretations, which might be associated with scores (Lezak, Howieson, Lorin & 
Fischer, 2004). This is crucial since MS is particularly heterogeneous (Disanto et al., 
2011). These personal factors could contribute in some way with cognitive 
performance, including those which have been outlined in the literature below. 
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3.2.15. Mood and anxiety  
Depression and anxiety are the most commonly experienced mental health problems 
in MS (Turner et al., 2016). These factors have been shown to impact on objective 
cognitive performance in MS (Nunnari et al., 2015), in areas such as IPS, visual-spatial 
memory and executive functioning (Morrow, Rosehart, & Pantazopoulos, 2015).  
 
3.2.16. Fatigue 
Fatigue is extremely common in MS (50% - 90%) and negatively impacts on quality of 
life and employability (Amato et al., 2001; Flensner, Landtblom, Söderhamn, & Ek, 
2013). Fatigue impairs task endurance (Sandry, Genova, Dobryakova, DeLuca, & 
Wylie, 2014) and interferes with many aspects of cognitive performance, including 
speed of visual processing (Kluckow, Rehbein, Schwab, Witte, & Bublak, 2016), 
memory, visuomotor abilities and attention (Pokryszko-Dragan et al., 2016).  
 
3.2.17. Dexterity 
Most people with MS experience upper limb dysfunction, which leads to increased 
dependency and negatively impacts on quality of life (Lamers & Feys, 2014) and 
employment (Marrie et al., 2017). There are a variety of tools to assesses dexterity in 
MS, which include the Nine Hole Peg Test (9-HPT) and the Grooved Peg Test (GPT). 
These tests differ in their sensorimotor assessment, in particular the GPT is more 
complex and requires a higher level of motor planning demands than the 9-HPT.   
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3.2.18. Visual Functioning 
Problems with vision are a common manifestation in MS due to incomplete recovery 
from optic neuritis (ON) or impairment to the optic pathway occurring 
independently from ON (Oberwahrenbrock et al., 2012). A recent review 
demonstrated that high-contrast visual acuity (HCVA) remains functional in MS, but 
Low-Contrast Letter Acuity (LCLA) is impaired (Balcer et al., 2017). As might be 
expected, a correlation has been reported between LCLA and the Expanded Disability 
Status Score (EDSS) (Balcer et al., 2003), which is the gold standard for measuring MS 
disability (Kurtzke, 1983).  
 
3.2.19. Premorbid functioning 
Cognitive reserve is an important predictor of better performance on cognitive tests 
in individuals with MS (Chillemi et al., 2015; Modica et al., 2016; Nunnari et al., 
2016). In particular, a review highlighted that high premorbid intelligence improves 
neuropsychological functioning (Benedict & Zivadinov, 2011). High levels of 
education plays a protective role in MS with a short rather than long duration 
(Rimkus et al., 2018).  
 
3.2.20. Summary 
Cognitive assessment is central to the management of MS. There are several means 
of assessing cognition, which include MRI, patient report or neuropsychological 
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batteries. Traditional neuropsychological batteries are sensitive to cognitive 
impairment and offer an objective measure of performance compared to alternative 
methods. Yet they are lengthy and require specialist training and materials. The 
BICAMS can be completed in under 15 minutes and assesses the three most 
prevalent cognitive impairments in MS, using only paper, a pencil and a stopwatch. 
The recently developed iPad BICAMS is expected to offer the same benefits in 
assessment as the paper and pencil version, with the added assistance of automated 
display times and scoring. In addition to the need of a precise and time effective 
measurement of cognition, contextual factors are important when evaluating 
performance, particularly when MS is heterogeneous (Disanto et al., 2011). The 
objective of this study will be to confirm that the iPad BICAMS reaches the same 
level of agreement as the paper and pencil version and that patient satisfaction will 
be greater for the iPad version compared to the conventional form.  
  
3.2.21. Aim 
The main aim of the study will be to examine the level of agreement between the 
iPad and the paper version of the BICAMS in adults with MS, explore related factors 
which might influence cognition and investigate participant satisfaction with being 
tested by the iPad.  
 
3.2.22. Hypotheses 
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First Hypothesis 
There will be a high level of agreement between the iPad and paper BICAMS. 
Second Hypothesis 
There will be a negative association between performance on iPad BICAMS and 
mood, fatigue, visual functioning and dexterity. In addition there will be a positive 
association between premorbid intellectual ability and cognitive ability on the 
BICAMS.  
 
Third Hypothesis 
Participants will report that they perceive being tested by the iPad BICAMS as being 
more easy and enjoyable than the paper version.  
 
3.3. Method 
3.3.1. Research Approval 
The project received a favourable ethical opinion from the North East - Tyne & Wear 
South Research Ethics Committee following submission to a Proportionate Review 
Authority (ref: 17/NE/0352; see Appendix). The study was certified by the Research 
Ethics Committee at Royal Holloway, University of London. 
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3.3.2. Sample and setting 
Inclusion and Exclusion Criteria 
The inclusion criteria: 
(a) Diagnosis of MS by a Consultant Neurologist based on Polman et al. (2011) or 
equivalent 
(b) Aged between 18 – 65 years 
(c) Born and educated in England 
(d) Able to give informed consent 
The exclusion criteria: 
(a) Any other primary neurologic or psychiatric condition that might separately 
contribute to cognitive impairment.  
(b) A sensorimotor impairment that would confound the testing performance. 
 
The study took place within the Neurology department of the Royal London Hospital or at 
participant’s homes. The Clinical Trials Coordinator identified participants. Participants who 
had given consent to be contacted for research purposes were invited to take part in the 
study via email or were given the Information Sheet when they attended clinic 
appointments. No information was collected about response rate. 
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3.3.3. Materials and measures 
3.3.4. Premorbid Functioning 
The Test of Premorbid Functioning (TOPF) (Wechsler, 2011) eliminates premorbid 
intellectual functioning for individuals aged between 16-90 (see Appendix). 
Participants are instructed to read a list of up to 70 English words out loud. The 
words have atypical grapheme to phoneme translations. The number of correct 
responses are used in a calculation, in addition to the participant’s gender, age and 
years of education, to provide an overall premorbid full-scale intelligence quotient 
(Wechsler, 2011). According to the scale, scores are considered in the following 
ranges: 80 to 89 ‘low average’; 90 to 110 ‘average’; 110 to 119 ‘high average’; 120 to 
129 ‘superior’. The TOPF shows good test re-test reliability (r =.89 to .95) and high 
split-half reliability (r = .92 to r = .99) (Wechsler, 2011) and it has been utilised 
previously to assess premorbid function in MS (Berg, Durant, Banks, & Miller, 2016).   
 
3.3.5. Cognition 
3.3.6. Brief International Cognitive Assessment for Multiple Sclerosis 
The BICAMS (Langdon et al., 2012) consists of three subtests (see Appendix) which 
assess the following areas of cognition:  
The Symbol Digit Modalities Test (SDMT) assesses IPS (Smith, 1982). At the top of the 
SDMT record form is a nine-item key which contains symbols which are paired with 
numbers. The examiner instructs the participant to vocalise as quickly as possible the 
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numbers which correspond with the symbols presented in the empty boxes on the 
record sheet within a 90-second limit. The score is obtained by calculating the total 
sum of the correct responses.  
The SDMT-oral demonstrates excellent psychometric properties (Jaywant, Barredo, 
Ahern & Resnik, 2016), including test retest reliability (r = .80) (Smith, 1982) and 
moderate to high concurrent validity (correlations with WAIS Digit Symbol Coding 
subtest of r = .62 to r = .91) (Bowler, Sudia, Mergler, Harrison & Cone, 1992; Hinton-
Bayre, Geffen, & McFarland, 1997; Lewandowski, 1984; Morgan & Wheelock, 1992). 
The psychometric properties remain high in MS populations, the SDMT has good 
construct validity (Christodoulou et al., 2003), sensitivity (78-82%) and specificity (60-
69%) to cognitive impairment (López-Góngora et al., 2015; Parmenter et al., 2007) 
and it can distinguish adults with MS from healthy controls (HC) (Drake, Weinstock-
Guttman, Morrow, Hojnacki, Munschauer & Benedict, 2010; Hughes et al., 2011; 
Langdon et al., 2012; O’Connell et al., 2015). 
The California Verbal Learning Test II (CVLT-II) learning trials (Delis, Kramer, Kaplan  
& Ober, 2000) examines immediate verbal recall. The CVLT-II consists of a 16-item 
list of English words. The experimenter reads aloud the list at a rate of slightly slower 
that one word per second and the participant is asked to respond immediately once 
the last word has been read with as many words as they can remember in any order. 
The overall score is derived from the total sum of correct responses over the five 
trials.  
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The complete CVLT-II shows good psychometric properties yet these should be 
interpreted inferentially as only the first five learning trials appear in the BICAMS 
(Langdon et al., 2012). In MS samples the CVLT-II shows good sensitivity (61%; 
(Niccolai et al., 2015) and sensitivity to detect cognitive impairment (Strober et al., 
2009). In addition the CVLT-II has good test retest reliability (Benedict, 2005; Delis, 
Kramer, Kaplan & Ober, 2000).  
The Brief Visual Memory Test - Revised (BVMT-R) learning trials (Benedict, 1997) 
assesses immediate visual recall through the presentation of 2 x 3 geometric figures. 
These figures are displayed for 10 seconds before being removed from view for a 
total of three trials. The examiner instructs participants to draw these shapes 
accurately and in the same position as had been located on the stimulus sheet. 
Scores are assigned to the BVMT-R for accuracy and precision position on the matrix 
with a maximum possible score of 36.  
The BVMT-R has good psychometric properties, including good inter-rater reliability 
(r > .90), and good test-retest reliability (r = .80) (Benedict, 1997), although they 
should be considered as inferential as only the learning trials were conducted 
(Langdon et al., 2012). The test shows good sensitivity to cognitive impairment in MS 
(60) (Benedict et al., 2001; Langdon et al., 2012; Niccolai et al., 2015) and concurrent 
validity correlates strongly with measures of explicit memory (r= .65 to .80) 
(Benedict, 1997). 
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3.3.7. iPad BICAMS 
iPad BICAMS was developed using REACT.JS and REDUX frameworks and operates on 
a pair of Apple iPads. There is an examiner and participant version. The parameters 
of the iPad version are consistent with the original paper form, apart from the 
written instructions which have been amended to accommodate the iPad format. 
The web application securely, and in an anonymous form, automatically submits 
results to a centralised database on the bicams.net website using .NET MVC backend 
to provide secure Application Processing Interfaces (API) to retrieve and save 
processed data. The application automatically scores performance on the SDMT and 
CVLT-II while BVMT-R drawings are saved to be scored later by the examiner.  
 
3.3.8 Associated Factors 
3.3.9. Depression and anxiety 
The Hospital Anxiety and Depression Scale (HADS) (Zigmond & Snaith, 1983) contains 
14-items which assess depression and anxiety symptoms separated into two 
subscales (see Appendix). Each item is rated from 0-3, with higher ratings indicating 
higher symptom severity. Cut-offs of 0-7 (normal range), 8-10 (mild range), 11- 14 
(moderate range), 15-21 (severe range) have been recommended (Zigmond & 
Snaith, 1983). The scale has been validated for use in individuals with MS 
(Honarmand & Feinstein, 2009) and has been demonstrated to be more effective 
than the Beck Depression Inventory-Fast Screen (BDI-FS) at predicting functional 
outcomes in those with depression (Hanna et al., 2017). The anxiety and depression 
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subscales have been found to show good internal consistency (α = .82 and .83 
respectively) (Honarmand & Feinstein, 2009). Caseness for anxiety and depression 
has been reported at 8/21 with a specificity of 78% and sensitivity of 90% for anxiety, 
and a specificity of 79% and sensitivity of 83% for depression (Bjelland, Dahl, Haug, & 
Neckelmann, 2002). The scale has been shown to be sensitive to depression and 
anxiety in MS (Watson, Ford, Worthington, & Lincoln, 2014). A reliability analysis 
showed that showed the HADS-A and HADS-D reached acceptable reliability rates 
respectively (α = 0.82; α = 0.75). 
 
3.3.10. Fatigue 
The Fatigue Severity Scale (FSS) (Krupp et al., 1989) contains 9-items which assess 
the impact of fatigue on functioning over the previous week (e.g. motivation, 
physical functioning, employment) on a 7-point Likert scale (see Appendix). The sum 
of the total score is used to indicate overall fatigue, with a clinical-cut off for 
individuals with MS set at scores of 36 and above to demonstrate severe fatigue 
(Krupp et al., 1989). The FSS has been shown to demonstrate excellent internal 
consistency (α = .81) for people with MS and good test-retest reliability (Krupp et al., 
1989). The instrument demonstrates moderate test re-test reliability over six months 
and adequate construct validity (Learmonth et al., 2013) and for discriminate use in 
MS populations (Flachenecker et al., 2002). Cronbach’s alpha showed the FSS 
questionnaire to reach acceptable reliability, α =0.91. 
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3.3.11. Visual Function 
The Multiple Sclerosis Vision Test Battery (MSVTS) (Bullimore, 2016) contains vision 
tests, including HCVA, LCVA (at 2.5% and 1.25%) and Letter Contrast Sensitivity (LCS). 
These tests are logMAR visual acuity charts which are based on the well validated 
and used Bailey-Lovie acuity charts. In the visual acuity charts, a unique combination 
of 5 letters are shown, across 19 rows, and the letter sizes on each row gradually 
decrease. In the letter contrast sensitivity series, the charts are based on the same 
principles as the Pelli-Robson Chart and the same 10-letter set as the Bailey-Lovie 
visual acuity chart. Two letters are presented together in 0.1 log unit steps and there 
are 23 different combinations.  
The MSVTS is presented on an iPad with autobrightness set to halfway and room 
lights may be dimmed or left on. The MSVTS does not require external lighting. The 
screens were visually assessed for reflections which could obscure the letters and 
repositioned if necessary. Participants are instructed to read aloud the letters they 
could see, with both eyes open, starting with those of high contrast until no letters 
on a given page is read correctly. Participants were encouraged to study a page for 
several seconds and guess the letter, even if they claim to be unable to see anything. 
Scoring for the visual acuity charts was based on the lowest line recorded and the 
Snellen fraction was calculated as the test distance divided by the lowest line. 
Scoring for the letter contrast sensitivity charts was recorded by each individual 
letter read correctly and multiplying by 0.05. The iPad-based assessment of Low-
Contrast Visual Acuity shows good agreement with the superior Sloan testing in 
individuals with MS (Sattarnezhad, Farrow, Kimbrough, Glanz & Healy, 2017).  
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The ICD 10 visual impairment criteria (ICD-10 World Health Organization, 1992) were 
used to interpret logMAR scores for HCVA, LCVA (at 2.5% and 1.25%). A score of 0 
would indicate ‘normal vision’; 0.5 to 1.0 ‘moderate visual impairment’; 1.1 to 1.3 
‘severe visual impairment’; 1.4 or greater ‘blindness’. For contrast sensitivity, a Pelli-
Robson score of 2.0 signify normal contrast sensitivity of 100 percent. Thus scores 
less than 2.0 indicate poorer contrast sensitivity. A score of less than 1.5 indicates 
visual impairment and a score of less than 1.0 represents a visual disability (Parede, 
Torricelli, Mukai, Netto, & Bechara, 2013). 
 
3.3.12. Dexterity   
The Nine-Hole Peg Test (9HPT) (Mathiowetz et al., 1985) assesses dexterity (see 
Appendix). In the test participants are instructed to move nine pegs from the 
container to an empty hole, one by one, until all the holes are filled. Once all the 
pegs have been placed into empty holes the participant must return the pegs 
individually to the container. They are required to do this as quickly as possible. The 
other hand is required to stabilise the pegboard. The test is completed twice, once 
for each hand, starting with the dominant hand. Scores are calculated from the time 
taken to complete the task, with quicker scores indicating superior dexterity. The 
cut-off score of 33 seconds has been recommended to differentiate mild from severe 
upper limb dysfunction in people with MS (Lamers et al., 2014).  
The 9HPT has been included in the MS functional composite measure (MSFC) 
(Fischer, Rudick, Cutter & Reingold, 1999). The 9HPT has a high inter-rater (r = .84 - 
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.96) and intra-rater (r = .91 - .99) reliability (Solari, Radice, Manneschi, Motti, & 
Montanari, 2005) as well as excellent internal consistency (α = .93; and high test-
retest reliability (r = .88) (Rasova, Martinkova, Vyskotova & Sedova, 2012). 
Concurrent validity reported between the EDSS score and 1-year change (r = .27) 
(Cutter et al., 1999). The 9-HPT has been shown to reliably discriminate between 
individuals with MS and healthy controls (Feys et al., 2017). A poor performance on 
the 9HPT has been shown to be indicative of cerebellar atrophy (Ruet et al., 2014) 
(Van De Pavert et al., 2016). The 9HPT has been widely applied as an assessment of 
upper extremity tremor (Alusi, Worthington, Glickman, Findley, & Bain, 2000; Fox, 
Bain, Glickman, Carroll, & Zajicek, 2004).  
The Grooved Pegboard Test (GPT) (Matthews & Klove, 1964) assesses higher level 
dexterity. There are 25 holes in the GPT, participants are instructed to precisely 
orient and insert canoe-shaped pegs into differently oriented canoe-shaped holes. 
The researcher begins by placing five pegs in the top five holes and then instructs the 
participant to complete the remaining 20 sequentially from the opposite side of the 
board to the hand that they are using, completing a line and then returning to the 
opposite side from the hand that they are using, until all lines are completed. This 
procedure is completed once for each hand (beginning with the dominant hand) and 
a mean score is taken. 
Compared to the 9-HPT, the GPT requires more motor planning due to the nature of 
the orientation and insertion of the pegs. In this task there is only one correct 
orientation for the peg to be inserted into the hole. Since all holes are uniquely 
differently orientated, and thus the peg inserted must be synchronously orientated 
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to the hole. Scores are interpreted as lower scores indicating superior upper limb 
function. 
The GPT shows marginal to high test-retest reliability within healthy controls (r = .67 
to .86) (Dikmen, Heaton, Grant & Temkin, 1999; Levine, Miller, Becker, Selnes & 
Cohen, 2004; Ruff & Parker, 1993). The test has been shown to have modest 
concurrent validity with relation to tapping speed (Schear & Sato, 1989). GPT scores 
and activities of daily living in MS have been found to be weak to modestly 
associated (Kessler, Cohen, Lauer, & Kausch, 1991). A motor planning index (MPI) 
can be calculated by subtracting scores on the 9HPT from the GPT.   
 
3.3.13. Participant’s Feedback 
A short 8-item survey was developed for the current study to assess participants’ 
experience of using the BICAMS (see Appendix). Four 5-point Likert scale assessed 
participant’s enjoyment and ease of using both BICAMS tests.  A single 7-point Likert 
scale examined participant satisfaction at being tested by the iPad BICAMS on a 
yearly basis in the future. Participants were asked to state their preference of 
BICAMS versions. Participants were invited to provide feedback on the iPad BICAMS. 
 
3.3.14. Experimental Design  
A within-subjects cross-sectional counterbalanced randomised design was applied to 
compare the performance on the iPad BICAMS to the BICAMS. In other words, all 
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participants are exposed to each condition (iPad and paper and pencil BICAMS), the 
order of which has been randomised in a counterbalanced fashion, at a single time-
point. The sequence of administration of the battery of assessments was randomised 
using the Research Randomiser version 4 (Urbaniak & Plous, 2013) to reduce 
systematic practice and fatigue effects.  
 
3.3.15. Procedure 
Written informed consent was gained. Participants were reminded to use eyewear 
to correct vision if needed on the neuropsychological test battery. Testing was 
carried out by a single researcher (FC, a Trainee Clinical Psychologist), following 
demonstration of competence at administering the battery to DL. Standardised 
procedures were adhered to as per individual test guidelines for the 
neuropsychological test battery. An iPhone application stopwatch was used for 
timed tasks. Testing took place in a quiet clinic room in the hospital or at 
participants’ homes.  
 
3.3.16. Power Analysis 
A power analysis was conducted based on (Onoda et al., 2013) due to the similarity 
of the study design and participant sample. A one-tailed, a priori analysis of a 
correlation between an iPad cognitive assessment and another standardised 
neuropsychological test (Trail Making Test) in adults with Alzheimer’s Disease was 
 
 
107  
undertaken to estimate power for the study using G*Power software (Faul et al., 
2007). The power analysis specified a sample size of 55 service-users, holding an 
alpha at .05, with a power of .80.  
 
3.3.17. Statistical Analysis  
The data below are presented as means and standard deviations for continuous 
variables or proportions and frequency for categorical variables. One participant’s 
iPad BVMT-R data’s file became corrupted and so the mean value was imputed in 
place. Six participants were unable to discern letters presented with LCVA 1.25%. 
Z-scores were produced for each variable to visually investigate for the presence of 
outliers. The peg test data from two participants was excluded with scores above 2 
standard deviations from the mean. Histograms were generated to examine for 
normality, particularly considering any ‘floor effects’ and ‘ceiling effects’ of task 
performance. Positively skewed data according to the Shapiro-Wilk test was 
transformed using power transformations (2-4). This applied to the peg test data. 
Inverse power transformations were used to gain normality sufficient for parametric 
analysis for negatively skewed data. This was true for the BVMT-R scores. 
Descriptive statistics were produced based on the socio-demographic and clinical 
characteristics of the sample (age, gender, years of education, diagnosis, duration of 
diagnosis, medication and mobility).  
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The mean scores and standard deviations of both versions of BICAMS were 
calculated. To examine the first hypothesis an intraclass coefficient correlation (ICC) 
was performed to investigate the level of agreement between BICAMS and iPad 
BICAMS across each subscale. ICC which are higher than .40 are commonly 
interpreted as evidence of scale reliability (Everitt, 2002). To examine order effects, 
six one way Analysis of Variance (ANOVAs) were performed. The mean and standard 
deviation of length of time to administer the iPad BICAMS was calculated. 
A composite score for cognitive impairment was calculated based on published UK 
norms for the SDMT, CVLT-II learning trials and BVMT-R learning trials (Orchard, 
Giovannoni & Langdon, 2013). A score of 0 was assigned if a participant scored 
greater than or equal to the published norm. A grade of 1 was allocated if the 
participant scored less than one standard deviation below the mean. A score of 2 
was assigned if this was less than two standard deviations below the mean. The total 
sum of these grades was calculated across the subscales (Camp et al., 2005). 
Descriptive statistics were produced for the associated factors, which included 
premorbid functioning, state depression and anxiety, dexterity and visual 
functioning. Estimated premorbid IQ (pFSIQ) was calculated with the TOPF scorer 
programme (Wechsler, 2011). This calculates pFSIQ based on age, gender, TOPF raw 
score, and years of education. The motor planning index (MPI) was computed by 
subtracting the 9HPT from the GPT.  To investigate the second hypothesis, a series of 
bivariate correlations were performed to understand the individual associations 
between iPad BICAMS subscales and associated variables.  
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To examine the third hypothesis the mean and standard deviation of ratings on the 
experience questionnaire were calculated. Participants’ qualitative feedback was 
reduced into themed categories. Paired t-tests were conducted to examine 
differences between enjoyment and ease of BICAMS versions. Bivariate correlations 
were conducted to explore whether reported enjoyment and ease of testing was 
related to performance on the BICAMS. 
The threshold for statistical significance was defined to p < .05. The Bonferroni 
correction was applied to reduce Type II error. Data was analysed using the 
Statistical Package of the Social Sciences (SPSS), version 24 (IBM Corporation, 
Armonk, NY, USA). 
 
3.4. Results 
3.4.1. Descriptive and clinical characteristics of sample 
Forty individuals with MS completed the battery. An overview of the socio-
demographic and clinical characteristics are presented in Table 4. Two thirds of 
participants were female. Participants’ ages ranged between 23 and 64 years. Years 
of education ranged from 11 to 21. Almost half of participants were in full-time 
employment. Most of the participants had RRMS. The duration of illness varied 
greatly between 1 and 35 years. Overall mobility was fair according to the Hauser 
Ambulation Index. 
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Table 4. Demographic and clinical characteristics of samples 
Characteristic     
Sex 
n (%) 
Female  
27 (67) 
Male  
13 (33) 
  
Age  
m (sd) 
 
45 (12) 
   
Education  
m (sd) 
 
16 (3) 
   
Employment  
n (%) 
Full-time  
19 (48) 
Part-time  
5 (12) 
Unemployed  
6 (15) 
Other 
10 (25) 
Phenotype  
n (%) 
RRMS  
32 (80) 
SPMS  
4 (10) 
PPMS  
4 (10) 
 
Duration  
m (sd) 
 
11 (10) 
   
Hauser 
Ambulation Index 
m (sd) 
 
2 (3) 
   
Medication  
n (%) 
 
Natalizumab 
18 (49) 
Alemtuzumab 
3 (8) 
 
Ocrelizumab 
3 (8) 
 
Other 
16 (35) 
     
Note. Mean (m); frequency count (n); Primary Progressive Multiple Sclerosis (PPMS); 
Relapse Remitting Multiple Sclerosis (RRMS); Secondary Progressive Multiple 
Sclerosis (SPMS); standard deviation (sd).  
 
3.4.2. Associated factors 
Table 5 presents the data related to premorbid functioning, mood, fatigue, dexterity 
and visual functioning. 
 
3.4.3. Premorbid Functioning 
The sample had above average pFSIQ, which ranged greatly from ‘low average’ to 
‘superior’. The mode was 114.   
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3.4.4. Depression and anxiety 
The mean state depression and anxiety levels within the sample fell within the 
‘normal’ range according to the HADS. However there were 11 cases in the clinical 
range for anxiety and 4 participants were above the cut off for depression. 
 
3.4.5. Fatigue 
The average level of fatigue reported fell above the cut-off level. Approximately 60% 
of participants’ scores were above the 36 cut-off for fatigue levels. 
 
3.4.6. Dexterity 
Upper limb function was considered to be in the mild range according to the 9HPT. 
Scores on the GPT were considerably higher, which reflects the additional sensori-
motor demands of the task. 
 
3.4.7. Visual functioning 
The mean HCVA for the sample fell within the range for ‘normal vision’. While the 
average LCVA for both 2.5% and 1.25% was considered ‘moderate visual 
impairment’. The LCS was below that signifying normal contrast sensitivity, but 
above the score for visual impairment. 
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Table 5. Premorbid functioning, mood, fatigue, dexterity and visual functioning  
Associated factors m (sd) Range 
TOPF 110 (12) 86-136 
HADS-A  8 (4) 2 -17 
HADS-D 6 (3) 0 – 14 
FSS 42.75 (13) 9 – 63 
9HPT  24 (7) 17 – 50 
GPT†   111 (44) 62 – 242 
MPI†  86 (34) 43 – 208 
HCVA  .10 (.17) -.18 - .50 
LCVA 2.5% .50 (.16) .03 - .86 
LCVA 1.25% .73 (.10) .50 - .94 
LCS 1.89 (.21) 1.15 – 2.15 
Note. Fatigue Severity Scale (FSS); Grooved Peg Test (GPT); High Contrast Visual 
Acuity (HCVA); Hospital Anxiety and Depression Scale – Anxiety (HADS-A); Hospital 
Anxiety and Depression Scale – Depression (HADS-D); Letter Contrast Sensitivity 
(LCS); Low Contrast Visual Acuity (LCVA at 2.5% or 1.25%); mean (m); Motor Planning 
Index (MPI); Nine Hole Peg Test (9HPT); standard deviation (sd); Test of Premorbid 
Functioning (TOPF). †n=38. 
 
3.4.8. Cognitive tests 
The results from the BICAMS tests are reported in Table 6. Three one-way random 
effects ICCs conducted between the versions of the BICAMS demonstrate above 
satisfactory levels of agreement. The ICC was greatest for the SDMT, followed by the 
BVMT-R and CVLT-II.  
Standard administration of BICAMS is reported to take under 15 minutes to 
complete. The average duration of administration of the BICAMS iPad in the current 
study was recorded as 13.21 minutes (sd= 2.61), which ranged from 8 to 25 minutes. 
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The order of administration of the BICAMS was evaluated across six one-way 
ANOVAs, since half of participants completed iPad BICAMS first and the other half 
completed paper and pencil BICAMS first. Using Bonferroni correction for multiple 
testing, one ANOVA was statistically significant (F(1, 39)=19.754, p<.001). The results 
show that performance on CVLT-II was poorer if participants were in a condition 
which received the paper version first. The results could be attributed to the 
superior internal validity of the iPad BICAMS (e.g. display times, reading times) 
compared to the paper and pencil version which may be limited by examiner error. 
The iPad BICAMS provides a cue for when the examiner should give the verbal 
stimuli in the CVLT-II, while the examiner uses a stopwatch as a guide when 
administering the paper and pencil version. The findings may not have been found in 
the opposite direction, due to practice effects.  
An index of cognitive impairment calculated based on iPad BICAMS scores showed 
the following distribution. Two people scored less than 2 standard deviations from 
the published norms on the SDMT. While 10 participants scored less than 1 standard 
deviation from the published norms for that subscale. For the BVMT-R, 2 people 
scored less than 2 standard deviations from the published norms. There were 6 
participants who scored less than 1 standard deviation from the published norms on 
the BVMT-R. In the CVLT-II, only five participants scored less than 1 standard 
deviation from the published norms. All of the remainder of scores were greater 
than or equal to the published norm. There was no significant difference between 
impairment on either subscale (F(1, 78)=2.646, p=.077). 
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Table 6. BICAMS performance and level of agreement  
  m   (sd) Interclass correlation 
SDMT  iPad 
Paper 
50.13  
47.83  
(14.37) 
(12.33)  
.85, 95% CI (0.74, 0.92), p < 
.001  
CVLT-II  iPad 
Paper 
55.73  
53.68  
(17.10) 
(14.01) 
.57, 95% CI (0.32, 0.75), p < 
.001 
BVMT-R  iPad 
Paper 
23.40  
23.30  
(10.69)  
(8.12) 
.67, 95% CI (0.45, 0.62), p < 
.001 
Note. Brief Visual Memory Test Revised (BVMT-R); California Verbal Learning Trials II 
(CVLT-II); mean (m); standard deviation (sd); Symbol Digit Modalities Test (SDMT). 
  
3.4.9. Correlations Analysis  
A series of bivariate correlations were performed to understand the individual 
associations between iPad BICAMS subscales and associated variables (see Table 7). 
Only the following associations were significant following Bonferroni correction for 
multiple testing. The SDMT was significantly negatively related to MPI (r = -.469, p 
=.002). The BVMT-R was significantly negatively related to HCVA (r = -.459, p =.003). 
No other correlation analysis reached statistical significance. Motor and visual 
function are not necessary for immediate verbal auditory recall (CVLT-II), therefore 
correlations were not performed for between these variables. Fisher’s z-
transformation was performed to obtain confidence intervals for the correlations. 
The confidence intervals for the above correlations overlap with 0 and so the effects 
will no longer be significant (SDMT and MPI: CI= .08, .73; BVMT-R and HCVA: CI= -.72, 
-.07). 
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Table 7. Correlations between iPad BICAMS performance and associated variables  
 iPad SDMT iPad CVLT-II iPad BVMT-R 
HADS-A r= .175, p= .280 r= .044, p= .788 r= .046, p= .776 
HADS-D r= .007, p= .965 r= -.060, p= .714 r= .039, p= .811 
FSS r= -.077, p= .639 r= .056, p= .734 r= .002, p= .988 
MPI r= -.469, p= .002 - r= .028, p= .863 
HCVA r= -.205, p= .204 - r= -.459, p= .003 
LCVA 2.5% r= .397, p= .011 - r= -.283, p= .077 
LCVA 1.25% r= -.192, p= .276 - r= -.275, p= .115 
LCS r= .196, p= .226 - r= .318, p= .045 
Note. Fatigue Severity Scale (FSS); Motor Planning Index (MPI); High Contrast Visual 
Acuity (HCVA); Hospital Anxiety and Depression Scale – Anxiety (HADS-A); Hospital 
Anxiety and Depression Scale – Depression (HADS-D); Letter Contrast Sensitivity 
(LCS); Low Contrast Visual Acuity (LCVA at 2.5% or 1.25%); Brief Visual Memory Test 
Revised (BVMT-R); California Verbal Learning Trials II (CVLT-II); Symbol Digit 
Modalities Test (SDMT). 
 
A linear regression revealed a significant relationship between MPI and SDMT (p < 
0.001). The slope coefficient for gestation was - 0.08. The R2 value was 0.22 so 22% 
of the variation in SDMT can be explained by the model containing only MPI. 
 
3.4.10. Participant feedback 
Seventy percent of participants reported that they would be ‘moderately’ to ‘very 
satisfied’ to be tested by the BICAMS iPad on a yearly basis in the future. Participants 
scored the level of enjoyment and ease exactly the same between iPad and paper 
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versions of BICAMS. There was no discernible difference between preferences of 
either version of BICAMS. More participants rated that they had no preference over 
iPad version (n=16, 40%), than those that stated favouring either the iPad (n=12, 
20%) or paper BICAMS (n=12, 20%). The written feedback from participants who 
stated a preference was reduced into the following categories: ease of testing, an 
element of independence on test, favouring interacting with technology, 
engagement with tests, enjoyment of the test and maintaining a level of control 
while being tested. Response rates were too low to perform formal analysis of the 
categories. 
 
3.5. Discussion 
Cognitive impairment is amongst an array of symptoms in MS (Benedict & Zivadinov, 
2011). Assessing cognition is of vital importance since cognitive impairment is 
related to a host of poor outcomes. Comprehensive neuropsychological batteries 
offer advantages over patient report, clinical interview and MRI which lack specificity 
(Rocca et al., 2015; Romero et al., 2015). However these batteries often take a long 
to conduct and require access to specialist materials and training.  
The BICAMS was developed in 2010 to optimise cognitive assessment in MS. The test 
can be completed in under 15 minutes by most healthcare professionals. While MRI 
parameters do not correlate well with cognition (Mollison et al., 2017), the BICAMS 
offers an objective way to assess the three most impaired domains of cognition, 
which include the SDMT for IPS, the CVLT-II for immediate verbal recall and the 
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BVMT-R for immediate visual memory. For best part of the last decade the BICAMS 
has become increasingly adopted as an objective tool to assess cognition in MS. In 
2018 the BICAMS iPad was developed, with the objective to further refine the 
validity of the assessment. With all physical parameters kept constant with the paper 
version, the iPad BICAMS offered the addition of automated scoring and 
presentation times and assessment of visual functioning and drawing ability.  
Thus the primary aim of this study was to investigate the level of agreement 
between the iPad BICAMS and the paper version. The secondary objective was to 
explore relationships between associated factors, such as premorbid functioning, 
mood, dexterity and visual functioning, and cognitive performance on iPad BICAMS. 
The final aim was to explore participant’s experience of using iPad BICAMS.  
In line with the first hypothesis the level of agreement between the BICAMS iPad and 
the paper version was above that considered to be satisfactory on all scales. The 
agreement was particularly strong between the SDMT scales, compared to the CVLT-
II and BVMT-R. The SDMT has previously been recommended by an expert 
committee to be the most reliable, valid and sensitive screening test for cognitive 
impairment in MS (Langdon et al., 2012). The SDMT is more accurate in defining 
cognitive impairment than self-report (Kim et al., 2017). The IPS was been presented 
as the primary cognitive deficit in MS (Costa et al., 2016). The findings of this study 
provide support for this to some extent, although the SDMT task does require 
aspects of visual memory and oral-motor ability (Patel, Walker, & Feinstein, 2017b). 
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The finding of a moderate level of agreement between the CVLT-II and BVMT-R iPad 
and paper forms is not unsuprising. This could be explained by a number of factors. 
Firstly, previous literature has suggested that cognitive impairment in the domains 
assessed by these tasks are second to that of IPS dysfunction (e.g. Grzegorski & Losy, 
2017). Secondly, while the psychometric properties of these tests in MS are good 
they include the delayed recall condition. Therefore they should be interpreted 
cautiously when evaluating cognitive performance.      
Cognitive impairment, which ranged between 1.5 – 2 standard deviations below the 
healthy norm, was 30% in the current study. This is relatively low compared to the 
reported prevalence in other studies. A recent large multicentre trial reported 
approximately 50% of those with RRMS had a cognitive impairment (Ozakbas et al., 
2017). Cognitive impairment in the current sample may have been lower than that 
reported in previous literature for a number of reasons. Firstly, most participants had 
RRMS compared to SPMS or PPMS, cognitive impairment is more common is 
progressive forms of the disease. Secondly, the premorbid intelligence of the sample 
was above average. Greater premorbid functioning is a protective factor against 
cognitive decline (Chillemi et al., 2015). Thirdly, half of participants were taking the 
same medication, DMDs slow disease progression, which potentially includes against 
cognitive decline.  
The iPad BICAMS shows a similar level of internal validity as other cognitive 
assessments developed for neurodegenerative populations. The CADi showed alpha 
values over 0.7 (Onoda et al., 2013) and the C3-PAD had excellent validity between 
home and treatment conditions (0.93) (Rentz et al., 2016). Similar to the paper 
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version, the testing time took under 15 minutes. An order effect was observed in the 
CVLT-II subscale, with a trend for better performance if the paper version was 
administered first. This could be interpreted in the context of increased validity of 
the iPad version of the test supported with automated pacing of stimuli. 
To investigate the second hypothesis, the exploratory analysis revealed only an 
inverse association between MPI and iPad SDMT. High contrast visual functioning 
was related to the BVMT performance. The MPI was found to predict scores on the 
SDMT. This finding is not unexpected as most individuals with MS have an upper limb 
dysfunction (Lamers & Feys, 2014). It is interesting to note by the direction of this 
association, which suggests that upper limb function and cognitive ability are not 
synchronous. In addition, HCVA has been found to remain functional in people with 
MS (Balcer et al., 2017). Since the geometric figures in the BVMT-R are presented at 
a high contrast level, it can be expected that HCVA would correlate with 
performance in this domain.  
It was surprising to find that mood and anxiety did not correlate with performance 
on the iPad BICAMS. Since depression and anxiety are the most commonly 
experienced mental health problems in MS (Turner et al., 2016). It has been reported 
that mood may impact on cognitive performance in MS (Nunnari et al., 2015), in 
domains including IPS and visual memory (Morrow et al., 2015). Depression has been 
shown to account for around a 20% reduction in processing speed on the SDMT (V. 
Patel & Feinstein, 2018).  The lack of a relationship between depression and 
cognitive performance might be explained by depression scores being in normal 
range in the current study. In addition other studies have used alternative self-report 
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methods, including the BDI (e.g. Golan et al., 2018), which may be influenced by 
somatic symptoms.  
In addition, we found that fatigue did not correlate with cognitive performance. As 
most of the sample reported high levels of fatigue it was expected this would 
influenced cognitive ability, in areas such as visual processing (Kluckow et al., 2016), 
memory and attention (Pokryszko-Dragan et al., 2016). In addition, premorbid 
intelligence was not found to be related to neuropsychological functioning (Benedict 
& Zivadinov, 2011). These deviations from expectations may have been related to 
issues of statistical power. 
The third hypothesis was marginally supported since the majority of participants 
rated that they would be ‘moderately satisfied’ to ‘very satisfied’ to be tested by the 
BICAMS iPad on a yearly basis in the future. Participants were indifferent about the 
BICAMS format, there was no difference between preferences of either version of 
the BICAMS. For those that did state preferences, there was a trend for participants 
to prefer to use the paper version for ease.  
 
3.5.1. Strengths 
There are many positive features of this study which need to emphasised. Firstly, the 
use of a standardised and validated battery within the MS population limits bias. The 
materials selected have already been shown to be sensitive within this group. 
Randomising the order of testing of the iPad or paper BICAMS, supported with 
exploring the impact of order effects. The CVLT-II was found to be most influenced 
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by this. Therefore it is likely that the automated timing of the word list in the iPad 
BICAMS improves internal validity to some extent within that subscale.  
Secondly, this was the first study to include a measure of participant experience of 
the BICAMS assessment. Participant experience is an important factor to have 
considered. Understanding how people with MS perceive cognitive assessment could 
improve engagement with neuropsychological tasks. Particularly if the iPad BICAMS 
is used as intended on a yearly basis.  
Thirdly, only a single data point from iPad was not uploaded correctly from a sample 
of 40 participants. This means that the iPad BICAMS has a relatively low error rate. 
Thus healthcare professionals using the tool can be quite confident in its reliability.  
Particularly in busy clinic settings where the iPad BICAMS may be used up to several 
times a day. 
 
3.5.2. Limitations 
There are some shortcomings of this research which need to be considered. Firstly, 
response rate was not recorded for the study; therefore it is unclear about how 
representative the current sample is. Also the study was underpowered as it did not 
reach the suggested sample size. This may have impacted on statistical analysis 
between the iPad BICAMS performance and associated factors, including premorbid 
intellectual functioning, dexterity, mood and visual functioning. This was shown by 
the mild effect size of the correlation and that the confidence intervals overlapped 
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with zero (Greenland, Senn, Rothman, Carlin, Poole, Goodman & Altman, 2016). 
Therefore it is likely that the study was underpowered by the sample size. 
Secondly, the sensitivity of the visual function test may have been compromised by 
testing in different lighting environments, including participant home and hospital. 
However attempts were made to maintain consistency between testing 
environments to reduce bias. 
Thirdly, the majority of those who participated had RRMS phenotype. Fewer still had 
SPMS or PPMS, which prevented exploration of cognitive ability between groups. 
This is an important point since cognitive impairment is thought to be most marked 
in progressive forms of the illness. A recent meta-analysis showed that cognitive 
impairment, in the domains of memory was worse in individuals with PPMS 
compared to RRMS (Johnen et al., 2017), which will have clinical implications for 
targeted treatment. 
 
3.5.4. Future directions 
The iPad BICAMS has been successfully shown to have a moderate to high level of 
agreement with the paper and pencil form. There could be several ways which the 
iPad BICAMS could be validated in the future. Firstly, through reporting the internal 
consistency of the scale using Cronbach’s alpha. This may be particularly important 
for the CVLT-II and the BVMT-R immediate trials where psychometric properties 
were established for the assessments which include the delayed recall condition. 
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Secondly, to compare statistically between the internal validity of the BICAMS paper 
and pencil form and the iPad version.  
It will be important to establish the level of reliability of the iPad BICAMS through 
test re-test and follow-up designs. This would support the application of the BICAMS 
iPad within routine clinical appointments. This would improve understanding of the 
profile and trajectory of cognitive functioning in RRMS particularly.  It will be crucial 
to develop thresholds of clinical significance for BICAMS iPad scores, since it has 
been proposed that SDMT change approximating 4 points or 10% in magnitude is 
clinically meaningful (Benedict et al., 2017).  
It will be important to investigate the predicative validity of iPad BICAMS in 
identifying those at high risk of disability progression and poor clinical outcome 
(Pitteri, Romualdi, Magliozzi, Monaco, & Calabrese, 2017). The next steps will be 
using cognitive test performance alongside structural and functional imaging 
methods to improve validity of cognitive assessment associations (Benedict et al., 
2017) 
It will be necessary to use BICAMS iPad in trials of novel pharmacological treatments 
aimed at reducing cognitive impairment in MS (e.g. Cinar et al., 2017). A recent 
review discussed the pharmacological interventions for MS and highlighted novel 
strategies, such as cryostimulation, to target cognitive impairment (Miller, Morel, 
Redlicka, Miller, & Saluk, 2017).  
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3.5.5. Conclusion 
In summary, it has been demonstrated that the iPad BICAMS reaches the same level 
of agreement was the BICAMS paper version to assess cognition in MS. IPS appears 
to be related to motor planning.  
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4. Integration, Impact and Dissemination Summary 
 
4.1. Introduction 
Multiple Sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of 
the central nervous system (CNS) (Thompson et al., 2018). Cognitive deficits are 
among several other forms of physical impairments. Half of individuals with MS will 
have a cognitive impairment (Benedict & Zivadinov, 2011).  
 
4.2. Integration 
In this section I reflect on the process of integrating the chapters presented in the 
thesis. I discuss the extent to which I was able to unify the subcomponents, in what 
way I achieved this, and the context in which the final form took. As part of this 
section I highlight the importance of self-reflexivity in conducting research and what 
implications this had for the project in its final form.  
There are many different factors which determine the extent to which the 
subcomponents of the thesis were fully integrated. From a personal perspective I 
feel as though cohesion between the chapters was achieved to a significant degree. 
There is a clear argument which runs centrally through the pieces of work and most 
of the literature referenced in each section is repeated between the chapters which, 
to me, suggests that the thesis is well embedded within the wider evidence-base, as 
well as demonstrating a logical advancement to the field. In addition the chapters 
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can be considered to standalone as they offer novel and distinct contributions. In 
this way the thesis has achieved its original purpose.  
I felt that the chapters presented in the thesis were integrated well for a number of 
reasons. Firstly, the primary focus of the work was specific on a specific instrument. 
Having this anchor between the chapters supported with my clarity of thought and 
written expression. Throughout this project I found that decision making was simpler 
for this reason, which kept the project neat and contained.  
As an example, in the initial stages of supervision we discussed conducting a number 
of possible systematic review topics. We were clear from the beginning about the 
content of the empirical study. I decided to take forward the current idea, which was 
a review of the BICAMS validation studies, as other options felt too broad (i.e. quality 
of life in MS) and less central to the focus of the content of the empirical chapter. I 
was conscious about creating an overall narrative which built pragmatically from the 
systematic review through to the empirical study. 
In addition, once recruitment had ended on the iPad validation study I was able to 
visually compare performance on iPad BICAMS to those scores published in the 
BICAMS validation studies. It was comforting to observe that performance on the 
iPad BICAMS subscales were within the ranges of those studies published as part of 
the international validation protocol. For me, this was further confirmation that 
cohesion between the two chapters had been achieved. 
Secondly, I found that supervision was essential in managing synergy between the 
subcomponents. A clear research aim was set from the beginning which was 
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maintained by regular communication, a shared agenda and plan of actions. I found 
that in-between supervision rapid plan–do–study–act (PDSA) cycles took place 
(Taylor et al., 2014), which often presented novel challenges. I felt that supervision 
provided consistency throughout the project which prevented drift from the 
research aims at times when new or unexpected information could have redirected 
the course.  
I found that this was particularly the case during the initial planning stages of the 
thesis. I had no experience of MS prior to undertaking the research project and only 
a limited understanding of the evidence-base in the field. I reflected that as a Trainee 
Clinical Psychologist, I felt privileged to have been supervised by two Professors who 
each have a strong international research portfolio. With this support I was able to 
quickly improve my understanding of MS. This, in addition to, interactions with 
participants, enabled me to transfer my knowledge from theory to practice. From 
these experiences I was able to critically reflect on the BICAMS and thus confidently 
develop Discussion sections about the tool. 
Thirdly, the process of writing was cyclical and I found myself occupying many meta-
views in the development of the final form. I was aware of keeping in mind the 
agreements from supervision, the course requirements, how to maintain the 
confidentiality of service-users and to acknowledge the support of the neurology 
team at the Royal London Hospital. This type of writing process is quite typical. 
According to the cognitive process theory of writing (Flower & Hayes, 1981), the 
interaction between the writer’s defined topic, audience and writing plans and the 
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components of the writing process, including planning, translating, reviewing and 
monitoring, can occur individually or in tandem, in any order or repeatedly.  
Having conducted the systematic review first followed by the empirical chapter, I 
could see the value and potential of the iPad BICAMS. I found that being able to 
understand the importance and need to conduct the empirical study supported me 
to focus my thoughts and motivate me to complete the project. I remember feeling 
surprised by the number of countries that had participated in the international 
validation protocol. From reading their articles, as part of conducting the systematic 
review, I felt confident to describe the link between the systematic review and 
empirical chapter. 
The final form was developed through an accumulation of processes of positive 
interactions between various stakeholders, including myself, my supervisors, the 
course research subcommittee, the NHS ethical approval processes, the recruitment 
site and the participants. This dynamic was not always straightforward and I found 
that a challenge was managing multiple demands simultaneously. The 
subcomponents were developed in different timescales, which was useful as the 
outcomes could be translated through to the other working subcomponents. For 
example, in reviewing the validation studies I was aware of the descriptions of the 
task, and so I focused on explaining this in systemic terms (e.g. who delivered the 
task, their profession, their training).    
A potential challenge to the completion of the final form was my involvement in all 
aspects of the project, in particular, I was not blind to the hypothesis and aware of 
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the direction anticipated and I administered the tasks. I wonder what this bias may 
have contributed to in terms of the overall project. A benefit of this study was the 
inclusion of the participants’ experience survey, where participants were given the 
opportunity to express their views openly about the BICAMS. I found that this was 
refreshing and allowed service-users to have an active voice within the final form. 
For me, this contribution added an estimation of ecological validity which had been 
omitted from the initial plans for the thesis. The decision to develop and include the 
survey came later after the initial planning stages, but has proved integral to our 
understanding about the validity of BICAMS.     
A further aspect to consider, in terms of integration is the link between the findings 
in the study and its practical applications. I felt that I could make quite direct links 
between how the BICAMS iPad version could be realistically used across services and 
knowing this was both rewarding and motivating which helped me to drive forward 
to complete the piece of work.  
 
4.3. Impact 
The novel and distinct contributions within this thesis, which include the production 
of the systematic review and the empirical study, have a significant impact on clinical 
psychology for a number of reasons which have been outlined below.  
Firstly, related to the selection of the most effective form of cognitive assessment. 
Although the paper and pencil BICAMS has increased the availability of cognitive 
assessment within MS, by requiring less training to administer and improved 
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accessibility outside of MS specific centres, there was need for the development of 
the iPad version. The iPad BICAMS has demonstrated good psychometric properties 
within the empirical study, which suggest that it will have a great impact on future 
cognitive assessment in MS. This is primarily for six reasons, since it: (a) has 
increased the validity of the tool, which includes timings and automatic scoring (the 
latter will be available for the BVMT-R shortly); (b) has allowed for clinical 
assessment and management of cognitive performance to be more widely available; 
(c) has improved participant engagement with cognitive assessments, participants’ 
reported that the would be highly agreeable to be tested via the iPad BICAMS on a 
yearly basis in the future; (d) has demonstrated psychometric rigour which will 
enable drug trials involving pharmaceutical companies, such as Novartis, to use 
computerised assessments of cognition; (e) with enabling of the former benefit, to 
develop more drugs with MS therapeutic efficacy; and (f) will be linked with 
Electronic Health Records (EHR), which are increasingly being adopted and invited in 
within the United States (69%) and Canada (57%) (Borycki, Newsham, & Bates, 
2013).  
Secondly, related to the profile of cognitive assessment in MS. It is highly likely that 
the meta-analysis of the BICAMS scores generated from the international validation 
protocol can be used as supporting evidence for the importance of conducting 
cognitive assessments in routine clinical appointments. This could be through 
supporting with cases to spend part of clinical budgets on two iPads to run the 
BICAMS software. Up until the production of the BICAMS validation studies there 
had not been a tool which had been consistently applied to assess cognition in MS 
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internationally. The pooled sample size of the individuals with MS included in the 
meta-analysis was 1,599. Therefore the demonstrated validity of the BICAMS across 
countries could encourage its use in countries which have yet to validate the 
BICAMS. Understanding and confidence in the BICAMS may have been improved in 
the MS community at large.  
Thirdly, the development of the thesis marks the success of the international 
collaboration to improve cognitive assessment in MS. The cooperation of the 
international MS community has been ongoing since recommendations for the 
BICAMS were published in 2010 (Langdon et al., 2012). The BICAMS appears to have 
now superseded its predecessors and has been widely adopted as the most common 
form of cognition assessment in MS. It is likely that the findings in the thesis will 
therefore have a significant impact in research terms. As described in the chapters 
within the thesis, there are many points of interest to study, such as the association 
between BICAMS performance and quality of life, efficacy of disease modifying drugs 
(DMDs) and test re-test reliability of the tool. 
Perhaps among the most important questions will be related to treatment. Specific 
cognitive rehabilitation for MS is arguably the most effective form of intervention. It 
is possible that the findings of this thesis could be used as evidence to support the 
use of the BICAMS in clinical trials of cognitive rehabilitation. Several previous 
systematic reviews described that the heterogeneity of the evidence surrounding 
cognitive rehabilitation in MS was less than satisfactory. Therefore there is a strong 
case for the use of the BICAMS as a standard measure of cognitive ability across 
study trials to examine the effectiveness of cognitive rehabilitation. 
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Fourthly, related to translating the findings of the thesis across to theoretical 
orientations about cognition in MS, the meta-analysis showed that IPS was reduced 
in people with MS compared to HC, with a largest effect size. This is consistent with 
earlier literature which reported that IPS is the most prevalent cognitive impairment 
in MS. It had been previously proposed that IPS presents as the core cognitive deficit 
(Costa et al., 2016). Although the results from this thesis are unable to confirm or 
disconfirm this notion at present, they will, however, contribute incrementally 
towards to the long term better understanding of models of cognition in MS. 
Given the cross-sectional nature of the study designs and lack of randomization 
between participants in the articles included in the systematic review it is unclear 
whether reduced IPS is a contributor to or consequence of impairments in other 
domains. However, given the overall finding it is highly likely that impaired IPS plays 
an important role in cognitive dysfunction in MS.  
Interestingly a medium effect size was found between both immediate recall tests, 
which could suggests that MS impacts on verbal and visual recall in a similar way. 
Earlier theories pointed to difficulty with immediate verbal recall being a result of a 
deficit in acquisition than retrieval. It could be suggested that acquisition of visual 
information is impaired in MS. This may be facilitated by visual acuity impairments, 
particularly related to LCVA than HCVA, as this was found to be non-affected in 
people with MS in the current empirical study. Further research will need to be 
conducted regarding the model of cognitive impairment in MS to support this 
interpretation. 
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Fifthly, I have reflected on the process of developing this thesis and the impact that 
it has had on me, in terms of my own personal and professional development. As I 
stated earlier, I had no prior experience of working with individuals with MS. 
Fortunately I had been able to complete several neuropsychological placements as 
part of training, which helped me to feel confident about conducting research 
regarding neuropsychological assessment.    
While collecting data I noticed that as the literature had explained, MS symptoms 
were broad and varied. I had expected that most participants would be in 
wheelchairs. However I was surprised and comforted to learn that DMDs were able 
to reduce the mobility deterioration. I was particularly taken aback by participants’ 
performance on the Grooved Peg Test (GPT). I had not administered this assessment 
before so I had limited expectations about participants’ performance. Many 
participants completing this test challenging. It was difficult for me to observe 
participants in a moment of frustration. I reflected that this assessment, and others 
included in the battery, produced this response as they were sensitive to detect 
specific impairments in MS.  
When analysing the results it came as no surprise to me that the average sample 
premorbid intellectual function was above average. From listening to participants’ 
stories it was clear how MS had negatively impacted on their ability to carry out 
tasks which they had previously been able to perform well on. I noticed myself 
empathising with their position, understanding their loss motivated me to want to 
support them and others with MS with the validation of the iPad BICAMS. 
 
 
134  
4.4. Dissemination 
 
Dissemination of the intervention to the specific audience forms an integral 
component of the Division 12 Task Force of the American Psychological Association, 
which aims to promote and support the integration of clinical psychological theory 
within practice. For the purposes of this research the intended audience is the MS 
community of individuals with MS and their families, clinicians and researchers, 
services and support groups.  
I based the dissemination plan for this audience on the guidance that the most 
effective form of dissemination in clinical psychology involves the adaption of the 
medium and language of the communication to suit the specific audience (Smith & 
Thew, 2017).  Therefore the findings from the current thesis, which have been 
described in the systematic review and empirical study chapters, will be 
disseminated widely, across a range of settings, to a large audience and in a variety 
of formats.  
 
4.4.1 Electronic dissemination 
Publication in peer-reviewed journals has been described as one effective method of 
sharing findings (Smith & Thew, 2017). At the time of writing this, I have submitted 
the systematic review and meta-analysis chapter for publication in the electronic 
peer reviewed scientific journal Neurology and Therapy. It was an invited review 
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which was accepted for publication in May 2018. The journal is relatively new and 
originated in the United States in 2012. It has a wide focus on observational, real-
world, and health outcomes research around the discovery, development, and use of 
neurological and psychiatric therapies, including devices.  
The paper published in this journal is likely to attract a large audience, given that it is 
open access and is published in the English language. Earlier research has outlined 
that English proficiency was one of the factors strongly associated with publication in 
the highest ranked general medical journals (Man, Weinkauf, Tsang, & Sin, 2004). 
Unfortunately, whilst it might be optimal to translate this publication, I do not have 
capacity to do this at present. This is a limitation in the dissemination plan, since MS 
has been shown to impact those individuals in non-English speaking countries 
(Browne et al., 2014). Despite this shortcoming, the paper was accompanied by a 
bulleted summary slide, which offered a time-efficient way of sharing the 
information from the article. 
The empirical study chapter will be written up for publication in a peer reviewed 
scientific journal following submission of this thesis. The target journal for this will be 
Multiple Sclerosis, which is a peer-reviewed journal which originated in the United 
States in 1995. This journal was selected as its scope is on the aetiology and 
pathogenesis of demyelinating and inflammatory diseases of the central nervous 
system and on the application of such studies to scientifically based therapy. In 
addition this journal has a high H Index at 101. 
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In addition to dissemination in journal format, I plan to publish a summary of the 
study in other forums, including via the MS Trust and MS Society. There are two 
main benefits of this type of dissemination for improving access, firstly that this time 
they will be written up as articles by patients with MS and secondly they will be 
published as newsletters or on the appropriate website for the specific audience. 
The MS Trust and MS Society are well established organisations that have a high 
profile within the MS community. Including service-users in dissemination is a critical 
feature of the dissemination process, since service-users can consult on the 
promotion of the research (Tabak, Khoong, Chambers, & Brownson, 2012), since the 
background of the person sharing the information can influence the speed at which 
the innovation is disseminated (Cockerill & Barnsley, 1997). 
I cited Royal Holloway, University of London, as both my and my Supervisor’s 
affiliation on the publication. The publication of this paper is likely to have a positive 
impact on the research capital of Royal Holloway, University of London, since the 
quality of research outputs, including publications, in the United Kingdom are 
assessed by the Research Excellence Framework (REF). Further, the publications will 
contribute my supervisor’s impact case for the department. In 2014 Royal Holloway 
was ranked within the top 25% of universities in the UK for research which is 
recognised as being ‘world leading’ (Holloway, 2014). This recognition may promote 
the research further among those involved in research within the MS community.  
The thesis, including the systematic review and empirical study chapter, will be 
submitted to the Doctorate in Clinical Psychology at Royal Holloway University of 
London and the electronic version be made publically freely available in PDF format 
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to download and view. This may further promote the research among student 
populations with MS.  
4.4.2. Non-electronic forms of dissemination 
Further to written channels of dissemination, the results will be shared in oral form. I 
will orally present the study summaries of the empirical study chapter at Royal 
Holloway, University of London’s Doctorate in Clinical Psychology research 
presentation day. In the audience will be Trainee Clinical Psychologists and 
Chartered Clinical Psychologists. This form of dissemination will involve peer-to-peer 
information sharing and will promote understanding of cognition in MS to those who 
will practice as clinical psychologists and may even work in services with those with 
MS. A benefit of this in-vivo form of dissemination is that audience members will be 
given the opportunity to pose questions directly to me and my supervisor following 
the presentation which may enhance awareness.  
I will conduct a second oral presentation for the Neurology service at the Royal 
London Hospital, which was the site for recruitment. The team includes neurologists, 
a clinical trails manager and clinical nurse specialists. This service hosts a number of 
research trials and my supervisor manages an MS website which is accessed by a 
large number of the service-users. I plan to write a study summary for the supervisor 
to publish this on his website (GG). I hope that this form of dissemination to those 
that work within MS will improve the awareness and recognition of cognitive 
impairment within MS. This form of promotion is important as the attitudes of 
mental health service providers can facilitate the effectiveness of dissemination 
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efforts (Aarons, 2004). It has been reported that having respected opinion leaders 
promote the research can be a more effective form of dissemination (Oxman, 
Thomson, Davis, & Haynes, 1995). 
I plan to provide a third oral presentation about the empirical study, which will be at 
a large international scientific conference. I have written up the results of the 
systematic review into the form of an abstract which has been submitted for a 
presentation at the European Committee for Treatment and Research in MS 
(ECTRIMS) annual meeting. ECTRIMS has been running for over 25 years and was 
chosen for dissemination as it has served as the world’s biggest scientific meeting 
about MS every year. Access to the conference comes at a fee, therefore there may 
be issues around my being able to present it. However at this conference delegates 
are encouraged to discuss their reflections through social media, including Twitter. 
Anybody following publically available accounts will be able to access short 
reflections about the study in this way.  
In sum, the particulars of this research have been, or are planned to be disseminated 
in a variety of written and oral forms, the former by both researcher and service-
user, through a wide range of channels, including online, newsletters, presentations, 
posters, and to a different audience, including online, in vivo and social media, with 
the intention of promoting the field of cognition in MS.  
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4.5. Conclusion 
The purpose of this thesis twofold, firstly to synthesise the BICAMS studies which 
had been produced as part of the international validation protocol and secondly, to 
validate the newly developed iPad BICAMS in a UK sample. The systematic review 
and empirical study focused on each of these individual aims. I reflected on how well 
I thought these two elements were integrated drawing from examples from the 
research process. I generally felt that both pieces work were embedded well within 
the existing literature base, particularly because of the focus on one instrument. The 
findings generated from each chapter are likely to have a significant impact in the 
field of cognitive assessment in MS. I discussed the likely areas of impact, including 
improving the profile of cognitive assessment in MS, contributing towards 
theoretical models of cognition in MS, influencing countries to participate in the 
international validation protocol and my own personal and professional 
development. Various methods of dissemination were highlighted to inform the MS 
community of the findings contained within the thesis. In conclusion, this thesis has 
shown that the BICAMS is an internationally valid tool to assess cognition in MS and 
that its predecessor, the iPad BICAMS, is a psychometrically sound and participant 
endorsed tool to assess cognition.  
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6. Appendix 
6.1. Funnel Plot of the Symbol Digit Modalities Test (SDMT) 
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6.2. Funnel Plot of the California Verbal Memory Test II learning trials (CVLT-II) 
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6.3. Funnel Plot of the Brief Visual Memory Test learning trials (BVMT-R) 
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6.7. Research and Development Confirmation E-mail Correspondence  
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6.8. Participant Information Sheet 
 
 
Validation of the IPAD version of the Brief International Cognitive Assessment 
for Multiple Sclerosis (BICAMS) 
Information Sheet 
My name is Freya Corfield and I am a Trainee Clinical Psychologist studying at Royal 
Holloway, University of London. You have been invited to take part in a research 
study, which is being conducted as part of my Doctorate in Clinical Psychology. 
Before you decide to participate, I would like you to understand what the research will 
involve and why it is being conducted. Below you will be given some information 
about the research and then you will be able to decide if you would like to take part. 
Please read this information carefully. If you have any questions, then please contact 
me using the email address at the bottom of the page. 
What is the purpose of this study? 
This research aims to test the effectiveness of an IPAD-based battery of tests and 
short online directional reaction time (DRT) test as an assessment to measures 
cognition (i.e. thinking styles) in adults with Multiple Sclerosis (MS). 
Who is eligible to take part? 
You have been invited to take part because we would like to make sure that the IPAD 
and DRT assessment are good measures of cognition.  
To take part in this study you will need to be  
• aged 18-65;  
• able to communicate fluently in English;  
• born and educated in the UK 
• able to give informed consent.  
 
Unfortunately, if you have any other primary neurologic or psychiatric condition, 
including a history of a condition (e.g. head trauma) that may separately contribute to 
cognitive impairment or a primary neurodevelopmental disorders (e.g. autism 
spectrum disorder, fetal alcohol syndrome) and/or a sensorimotor impairment that 
would confound the testing media, then you will not be able to participate. 
Participants will need to be ‘born and educated in England’ to reduce the number of 
variables which may interfere with the interpretation of the results. 
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Do I have to take part? 
No. It is your choice whether you participate or not and your participation is entirely 
voluntary. If you do decide to take part, then you are free to withdraw from the study 
at any time and you do not need to give a reason. If you decide that you want to 
withdraw then you can contact me with your name and I will delete your data. You 
will be able to withdraw up until the end of April 2018 when the data analysis for this 
study will be finalised.  
What would taking part involve? 
If you decide to take part, you will be asked to complete three brief questionnaires 
asking about your demographic details and levels of mood and fatigue. After this you 
will take part in six short tests which test your thinking styles by asking you to 
pronounce a list of words, sort pegs, decipher symptoms and remember information 
previously presented. Some tests will be timed and you will be informed if they are. It 
is estimated that the total time taken will be no longer than 90 minutes. At the end of 
the face-to-face assessment you will be provided with a token and a link for you to 
complete the online DRT in your own time. The DRT can be accessed via a browser 
on your smartphone, tablet or personal computer. The DRT takes less than 5 
minutes to complete.   
Are there any disadvantages or risks to taking part? 
Although it is unlikely, it is possible that you may feel uncomfortable answering some 
of the questions you are asked or may find the questions distressing. If this is the 
case, the Patient Advice and Liaison Service at the Royal London Hospital – second 
floor central tower, near core lift 5 in the main building, is open 9:30am - 4:40pm 
Monday to Friday for independent advice. You are also free to not answer questions 
which you do not feel comfortable to. Your participation in this study will not affect 
your treatment as usual. 
Are there any benefits to taking part and what will happen to the results? 
It is hoped that this research will inform us about the how effective the test of 
cognition is in MS, since it is important to develop time and cost effective measures 
to administer in busy clinics. This research will contribute some understanding 
towards this. Unfortunately we are not able to give your individual scores, but you 
can request for a summary of the results when the research is completed. The 
results of the study will be written up as a doctoral thesis and submitted to an 
academic journal. The results may also be used in presentations about this work. 
The anonymised data will be entered into an international database for future meta-
analysis. Importantly, all of the information you provide will remain anonymous. 
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Will my information remain confidential? 
All of the information that you provide will remain anonymous. To keep your 
information confidential you will be assigned a unique identifying number. Individual 
responses will only be used by the researchers. The database will be stored on a 
password protected secure network folder on a Royal Holloway, University of London 
Computer accessed only by the Chief Investigator, Freya Corfield. Hard copies will 
be securely stored in locked filing cabinets in the Department of Clinical Psychology, 
Royal Holloway, University of London. The data will be stored up to 10 years for later 
analysis. 
Who can I contact about the study? 
If you have any questions about the study, please contact me using the following 
contact me using my e-mail address: freya.corfield.2015@live.rhul.ac.uk 
If you have any concerns about how the study is being conducted, you can contact 
my supervisor using e-mail or telephone:  
Prof. Dawn Langdon, d.langdon@rhul.ac.uk, 01784 443956 
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6.7. Consent Form 
 
Validation of the IPAD version of the Brief International Cognitive Assessment 
for Multiple Sclerosis (BICAMS) 
Consent Form 
You have been invited to participate in a research study exploring the use of a test on 
an IPAD to assess thinking styles in Multiple Sclerosis (MS).  
1. I confirm that I have read the information sheet dated 4th January 2018 
 (version 3) for the above study. I have had the opportunity to consider the 
 information, ask questions and have had these answered satisfactorily. 
2. I understand that my participation is voluntary and that I am free to withdraw 
 up until April 2018 without giving any reason, without my medical care or legal 
 rights being affected. 
3. I understand that relevant sections of my medical notes may be looked at by 
 the Principal Investigator where it is relevant to my taking part in this 
 research. I give permission for these individuals to have access to my 
 records.  
4. I understand that the information collected about me will be added to the 
 research team’s database to support research in the future 
5. I understand that relevant sections of my medical records and data collected 
 during  the study may be looked at by responsible individuals from the NHS 
 Trust or from  regulatory authorities, where it is relevant to my taking part in 
 this research. I give permission for these individuals to have access to my 
 records 
5. I allow access to study data for auditing and monitoring purposes 
6. I agree to take part in the above study.  
Participant 
Print Name:  ___________________________ 
Sign  ___________________________ 
Date  ___________________________ 
Person Taking Consent 
Print Name:  ___________________________ 
Sign  ___________________________ 
Date  ___________________________ 
Please 
initial 
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6.8. Fatigue Severity Scale (FSS) 
 
[Removed from online version] 
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6.9. Hospital Anxiety and Depression Scale (HADS) 
 
 
[Removed from online version] 
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6.10. Experience of BICAMS Survey 
After completing the iPad BICAMS, please select which of the following best fits with your 
opinion 
 
1. How easy did you find completing the test?  
Not at all 
easy 
Not easy Neutral Moderately 
easy 
Very easy 
     
 
 
 
2. How enjoyable did you find completing the test?  
Not at all 
enjoyable 
Not 
enjoyable 
Neutral Moderately 
enjoyable 
Very 
enjoyable 
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After completing the paper and pencil BICAMS, please select which of the following best fits 
with your opinion  
 
3. How easy did you find completing the test?  
Not at all 
easy 
Not easy Neutral Moderately 
easy 
Very easy 
     
 
 
 
4. How enjoyable did you find completing the test?  
Not at all 
enjoyable 
Not 
enjoyable 
Neutral Moderately 
enjoyable 
Very 
enjoyable 
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5. After completing all of the tests, which type of BICAMS did you prefer to 
be tested by? 
iPad paper and pencil No preference 
   
 
 
 
6. What was the reason for your choice? 
 
 
 
 
 
7. Compared to the paper and pencil version, how would you feel about 
being tested using the i-pad BICAMS on a yearly basis in the future? 
Very 
dissatisfied 
Moderately 
dissatisfied 
Slightly 
dissatisfied 
Neutral Slightly 
satisfied 
Moderately 
satisfied 
Very 
satisfied 
       
 
 
 
8. Any other feedback? 
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6.12. Nine Hole Peg Test (9HPT) 
[Removed from online version] 
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6.13. Grooved Peg Test (GPT) 
[Removed from online version] 
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6.14. BICAMS example Symbol Digit Modalities Test (SDMT) 
 
 
Copied from Langdon et al., 2012, with permission from author 
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6.15. BICAMS example California Verbal Learning Trials II (CVLT-II) 
Truck  
Spinach 
Giraffe 
Bookcase 
Onion 
Motorcycle 
Cabinet 
Zebra 
Coach 
Lamp 
Celery 
Cow 
Desk 
Boat 
Squirrel 
Cabbage 
Copied from Langdon et al., 2012, with permission from author 
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6.16. BICAMS example Brief Visual Memory Test Revised learning trials (BVMT-R) 
 
 
 
Copied from Langdon et al., 2012, with permission from author 
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6.17. BICAMS example of iPad screens  
[Removed from online version] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
